{"gene":"PABPN1","run_date":"2026-06-10T05:19:53","timeline":{"discoveries":[{"year":2001,"finding":"PABPN1 oligomerization is mediated by two potential oligomerization domains (ODs) in the protein; deletion of 6-8 amino acids in either OD prevents nuclear protein aggregation induced by polyalanine-expanded PABPN1, and prevention of aggregation significantly reduces cell death in COS-7 cells expressing mutant PABPN1.","method":"Deletion mutagenesis, exogenous expression in COS-7 cells, immunofluorescence microscopy, cell death assay","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — domain deletion mutagenesis with functional readout (aggregation and cell death), single lab, two orthogonal methods","pmids":["11689481"],"is_preprint":false},{"year":2003,"finding":"PABPN1 is associated with RNA polymerase II along the chromatin axis of the BR gene, suggesting it binds to the polymerase before, at, or shortly after the start of transcription; PABPN1 accompanies the released mRNP to the nuclear pore and is displaced from mRNPs during or shortly after passage through the nuclear pore.","method":"Cryo-immunoelectron microscopy on Chironomus tentans salivary gland Balbiani ring mRNP","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cryo-immunoelectron microscopy with spatial resolution, single lab, single method but high-resolution technique","pmids":["12749861"],"is_preprint":false},{"year":2003,"finding":"PABPN1 interacts with hnRNP A1 and hnRNP A/B (identified by yeast two-hybrid screen and confirmed by GST pull-down and co-immunoprecipitation); when co-expressed with mutant PABPN1 in COS-7 cells, hnRNP A1 and A/B co-localize with mutant PABPN1 in insoluble intranuclear aggregates, and hnRNP A1 is sequestered in OPMD nuclear inclusions in patient muscle.","method":"Yeast two-hybrid screen, GST pull-down, co-immunoprecipitation, immunofluorescence in COS-7 cells and patient muscle","journal":"The Canadian journal of neurological sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP and GST pull-down with cellular localization confirmation, single lab, multiple orthogonal methods","pmids":["12945950"],"is_preprint":false},{"year":2003,"finding":"Expanded polyalanine in PABPN1 N-terminal domain drives fibril formation with amyloid-like characteristics (antiparallel beta-sheets) in vitro; the lag-phase of fibril formation is reduced by seeding, and expansion to maximal OPMD length increases alpha-helical structure preceding fibrillation.","method":"In vitro recombinant protein assay, structural analysis (amyloid characteristics), seeding experiments","journal":"Protein science","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with structural analysis, single lab, multiple biophysical methods","pmids":["14627730"],"is_preprint":false},{"year":2005,"finding":"Normal (wild-type) PABPN1 is inherently aggregation-prone when exogenously expressed; protein domains required for stimulation of poly(A) polymerase are required for inclusion formation; FRAP experiments show both normal and expanded PABPN1 molecules move rapidly in and out of inclusions rather than being irreversibly sequestered.","method":"Exogenous expression in HeLa and C2 cells, domain deletion analysis, photobleaching (FRAP) experiments","journal":"RNA","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — live-cell FRAP and domain mutagenesis with functional readout, single lab, two orthogonal methods","pmids":["15811916"],"is_preprint":false},{"year":2005,"finding":"HSC70 and HSP70 chaperones interact with and localize to PABPN1 intranuclear inclusions; pharmacological induction of HSP70 (by ZnSO4, 8-hydroxyquinoline, ibuprofen, or indomethacin) recruits HSP70 and HSC70 into the nucleus and significantly reduces mutant PABPN1 aggregate burden and concomitant cell death.","method":"Pharmacological induction of heat shock response, confocal microscopy, solubility assay, cell death assay in HeLa cells","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pharmacological agents with orthogonal readouts (microscopy and solubility), single lab","pmids":["16239242"],"is_preprint":false},{"year":2006,"finding":"In a Drosophila model of OPMD, the RNA-binding domain of PABPN1 and its RNA-binding function are required for muscle degeneration, whereas the polyalanine tract is not absolutely required; this establishes that OPMD does not result purely from polyalanine toxicity but from an intrinsic property of PABPN1.","method":"Drosophila transgenic model, domain deletion/mutation analysis, muscle degeneration phenotype readout","journal":"The EMBO journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis via domain-specific mutants in an in vivo model, single lab, clear phenotypic readout","pmids":["16642034"],"is_preprint":false},{"year":2007,"finding":"Soluble forms of expanded PABPN1 (expPABPN1), not the insoluble nuclear aggregates, are the primary toxic species; interfering with large nuclear aggregate formation increases soluble expPABPN1 and significantly exacerbates cell death, as demonstrated by live microscopy.","method":"Live microscopy, aggregate disruption experiments, cell death assay in cellular OPMD model","journal":"Neurobiology of disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — live imaging with functional cell death readout, single lab, two orthogonal methods","pmids":["17418585"],"is_preprint":false},{"year":2008,"finding":"Wild-type PABPN1 exerts an anti-apoptotic function by regulating translation of X-linked inhibitor of apoptosis (XIAP) protein; overexpression of wild-type PABPN1 reduces mutant PABPN1 toxicity and protects cells from pro-apoptotic insults, while PABPN1 knockdown increases apoptotic susceptibility. This protective activity is partially lost for mutant PABPN1.","method":"Overexpression and knockdown in cell and mouse models, XIAP protein level measurement, apoptosis assay","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KD and OE with specific molecular target (XIAP), cell and mouse model validation, single lab","pmids":["18178579"],"is_preprint":false},{"year":2008,"finding":"Sirtuin SIRT1/sir-2.1 pathway and AMPK (aak-2) modulate mutant PABPN1 toxicity in muscle: increased sir-2.1 dosage exacerbates muscle pathology in a daf-16/FoxO- and aak-2/AMPK-dependent manner in C. elegans, while sir-2.1 null mutants are protective. SIRT1 inhibitor sirtinol promotes survival of mammalian cells expressing mutant PABPN1.","method":"C. elegans genetics (increased/null sir-2.1 dosage, double mutants), pharmacological treatment (sirtinol, resveratrol), mammalian cell survival assay","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis in C. elegans with pharmacological validation in mammalian cells, single lab, multiple orthogonal methods","pmids":["18397876"],"is_preprint":false},{"year":2009,"finding":"Expanded PABPN1 preferentially binds Hsp70 chaperones and type I arginine methyltransferases (PRMT1 and PRMT3) compared to wild-type PABPN1; these proteins accumulate at intranuclear inclusions in OPMD patient muscle. Molecular simulations suggest polyalanine expansion transitions PABPN1 from disordered to stable helical conformation, altering these interactions.","method":"Pull-down assays, immunofluorescence in patient muscle, molecular simulation","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — pull-down with patient tissue validation, single lab, two orthogonal methods","pmids":["19641605"],"is_preprint":false},{"year":2009,"finding":"Fission yeast PABPN1 ortholog Pab2 is cotranscriptionally recruited to active genes via nascent mRNPs (demonstrated by RNase-sensitive ChIP), with recruitment preceding that of typical 3'-processing/polyadenylation factors; Pab2 also associates with polysomes, suggesting it remains associated with translated mRNPs after nuclear export.","method":"Chromatin immunoprecipitation (ChIP) with RNase treatment, tandem affinity purification coupled with mass spectrometry, polysome fractionation","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP with RNase control and TAP-MS, single lab, multiple orthogonal methods; fission yeast ortholog","pmids":["19336419"],"is_preprint":false},{"year":2012,"finding":"Full-length PABPN1 forms amyloid-like fibrils in vitro independently of the alanine segment; fibril formation kinetics and denaturation resistance differ from those of the N-terminal domain alone, and FTIR spectroscopy plus limited proteolysis indicate the C-terminal domain is involved in fibril formation.","method":"In vitro fibril formation assay, FTIR spectroscopy, limited proteolysis, chaotropic denaturant resistance","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with structural analysis (FTIR, proteolysis), single lab, multiple biophysical methods","pmids":["22570486"],"is_preprint":false},{"year":2013,"finding":"Fission yeast nuclear poly(A)-binding proteins Pab2 (PABPN1 ortholog) and Nab2 have opposing roles in posttranscriptional regulation: Pab2 promotes nuclear pre-mRNA decay via the nuclear exosome subunit Rrp6, while Nab2 impedes Pab2/Rrp6-mediated decay by competing with Pab2 for polyadenylated transcripts in the nucleus.","method":"Genetic epistasis (double mutants), RNA decay assays, northern blotting in S. pombe","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis with RNA decay assays in fission yeast, single lab, multiple orthogonal methods; S. pombe ortholog","pmids":["24081329"],"is_preprint":false},{"year":2013,"finding":"A proline-tyrosine nuclear localization signal (PY-NLS) is necessary and sufficient for nuclear localization of fission yeast Pab2, functioning through Kap104 (Kapβ2 ortholog); however, neither a functional PY-NLS nor Kapβ2 activity are required for nuclear import of human PABPN1, indicating alternative or redundant import pathways exist for human PABPN1.","method":"NLS deletion/mutation analysis, nuclear localization assay, recombinant protein binding to Kap104, in vivo nuclear localization of human PABPN1","journal":"Traffic","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct nuclear localization experiments with domain mutagenesis and receptor binding assay, single lab, multiple orthogonal methods","pmids":["23279110"],"is_preprint":false},{"year":2014,"finding":"ARIH2 E3 ubiquitin ligase regulates PABPN1 protein accumulation and aggregation; PABPN1 controls ARIH2 mRNA levels via proximal polyadenylation site usage, forming a feed-forward regulatory loop. Masking the proximal polyadenylation site in ARIH2 3' UTR using antisense oligonucleotides elevates both ARIH2 and PABPN1 expression and restores myogenic defects.","method":"Antisense oligonucleotide treatment, protein accumulation and aggregation assay, RNA expression analysis, myogenesis assay","journal":"The American journal of pathology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — antisense oligonucleotide functional intervention with multiple readouts, single lab","pmids":["24486325"],"is_preprint":false},{"year":2015,"finding":"PABPN1 negatively controls its own expression (autoregulation) by binding to an adenosine-rich region in its own 3' UTR, which promotes retention of the 3'-terminal intron and clearance of intron-retained pre-mRNAs by the nuclear exosome; increased PABPN1 dosage reduces the spliced/unspliced transcript ratio and decreases endogenous PABPN1 protein levels.","method":"PABPN1 dosage manipulation, spliced/unspliced RNA ratio measurement, nuclear exosome knockdown, RNA binding analysis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — mechanistic pathway (PABPN1 → intron retention → nuclear exosome decay) established with multiple orthogonal methods and rescue experiments, single lab","pmids":["25963658"],"is_preprint":false},{"year":2015,"finding":"PABPN1 and poly(A) polymerase (PAP) coordinate splicing of a subset of introns that are excised after polyadenylation; PABPN1 promotes intron excision specifically in the context of 3'-end polyadenylation (not when bound to internal A-tracts), requiring its RNA-binding function and PAP-stimulatory function. N-terminal alanine-expanded PABPN1 cannot fully rescue PABPN1 depletion effects on this pathway.","method":"PABPN1 depletion (RNAi), PAP depletion, splicing assays, RNA-binding domain mutant analysis, exosome assays","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — domain-specific mutant analysis combined with depletion and exosome assays, single lab, multiple orthogonal methods","pmids":["25896913"],"is_preprint":false},{"year":2015,"finding":"PABPN1 suppresses TDP-43 toxicity; overexpression of full-length PABPN1 (but not a truncated form lacking the nuclear localization signal) promotes degradation of pathological TDP-43, restores normal TDP-43 solubility and nuclear localization, and facilitates removal of persistent stress granules. Reduced PABPN1 enhances TDP-43 pathological phenotypes and causes cytoplasmic mislocalization of TDP-43.","method":"Overexpression and knockdown in cell culture and Drosophila models, TDP-43 solubility fractionation, stress granule dynamics assay, nuclear localization analysis","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KD and OE with multiple orthogonal readouts in cell and Drosophila models, single lab","pmids":["26130692"],"is_preprint":false},{"year":2016,"finding":"Reduced PABPN1 levels in mouse tibialis anterior muscle cause consistent decline in distal polyadenylation site (PAS) utilization, leading to upregulation of Atrogin-1 (a key muscle atrophy regulator), reduced proteasomal gene expression and activity, and myofiber atrophy with extracellular matrix thickening.","method":"AAV-shRNA knockdown in mouse TA muscle, poly(A) site utilization analysis, gene expression profiling, proteasomal activity assay, histological analysis","journal":"PLoS genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo KD with multiple molecular and histological readouts, single lab","pmids":["27152426"],"is_preprint":false},{"year":2017,"finding":"PABPN1 interacts with Matrin 3 (MATR3) in mouse skeletal muscle (identified by co-immunoprecipitation and mass spectrometry); together PABPN1 and MATR3 regulate alternative polyadenylation, intron retention, paraspeckle morphology and function, Neat1 lncRNA levels, and adenosine-to-inosine (A-to-I) RNA editing of Ctn RNA in muscle cells.","method":"Co-immunoprecipitation, mass spectrometry, RNAi knockdown, alternative polyadenylation assay, paraspeckle morphology analysis, RNA editing assay","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP/MS for interaction identification plus multiple functional readouts, single lab, multiple orthogonal methods","pmids":["28977530"],"is_preprint":false},{"year":2019,"finding":"PABPN1 regulates SIRT1 mRNA levels via alternative polyadenylation site utilization; reduced PABPN1 leads to elevated SIRT1 deacetylase activity, decreased protein acetylation, and muscle wasting. SIRT1 deacetylase inhibition by sirtinol increases PABPN1 levels and reverses muscle wasting.","method":"Transcriptome and proteome comparison, acetylome profiling, SIRT1 expression analysis, sirtinol pharmacological treatment in shPAB mouse muscles","journal":"iScience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multi-omics with pharmacological rescue in vivo, single lab","pmids":["30739015"],"is_preprint":false},{"year":2019,"finding":"Expanded PABPN1 accumulates in mitochondria and interacts with the TIM23 mitochondrial protein import complex; both wild-type (10-alanine) and expanded (18-alanine) PABPN1 accumulate in mitochondria, but the 18-alanine form decreases cell viability and induces aggresome formation. Reduced OXPHOS complex expression was detected in transgenic OPMD mouse muscle.","method":"Mitochondrial fractionation, co-immunoprecipitation with TIM23, immunofluorescence in patient muscle and mouse model, OXPHOS complex expression analysis","journal":"Laboratory investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — subcellular fractionation and Co-IP with in vivo validation in patient and mouse tissue, single lab","pmids":["30894671"],"is_preprint":false},{"year":2020,"finding":"PABPN1 is necessary for p63α mRNA translation by modulating binding of translation initiation factors eIF4E and eIF4G to p63α mRNA; PABPN1 deficiency also increases p63γ mRNA through alternative polyadenylation in coding sequence. p63α (especially ΔNp63α) regulates PABPN1 transcription, forming a feedback loop that controls keratinocyte differentiation.","method":"PABPN1 siRNA knockdown, APA analysis, translation initiation factor binding assay (eIF4E/eIF4G co-IP), ectopic ΔNp63α rescue, keratinocyte differentiation assay","journal":"The Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP of translation factors with functional rescue, single lab, multiple orthogonal methods","pmids":["32243883"],"is_preprint":false},{"year":2022,"finding":"PABPN1 promotes the formation of nuclear poly(A) domains (NPADs) in mouse oocytes through liquid phase separation, driven by its N-terminal disordered domain and RNA-recognition motif; Pabpn1-null oocytes cannot form NPADs normally, have defects in transcript stability and long 3'UTR isoform formation, and Pabpn1-null mice are completely sterile with primary ovarian insufficiency.","method":"Pabpn1 knockout mouse model, live imaging of phase separation, domain deletion analysis, RNA-seq for 3'UTR isoform analysis, fertility assessment","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 2 / Strong — knockout mouse with domain analysis, phase separation imaging, and multiple functional readouts, single lab, multiple orthogonal methods","pmids":["36306357"],"is_preprint":false},{"year":2022,"finding":"PABPN1 has a cytoplasmic function in zygotic genome activation (ZGA)-dependent maternal mRNA clearance; cytoplasmic PABPN1 docks on 3'-uridylated transcripts downstream of TUT4/TUT7 uridyltransferases and recruits 3'-5' exoribonuclease DIS3L2 to facilitate maternal mRNA decay. Pabpn1 knockout embryos arrest at the morula stage with failure to remove Z-decay maternal mRNAs.","method":"Pabpn1 knockout mouse, RNA immunoprecipitation, DIS3L2 co-immunoprecipitation, RNA-seq of maternal mRNA decay, developmental stage analysis","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 / Strong — knockout mouse with mechanistic pathway placement (TUT4/7 → PABPN1 → DIS3L2) and multiple orthogonal validations, single lab","pmids":["34904664"],"is_preprint":false},{"year":2023,"finding":"PABPN1 promotes splicing of last introns with weak 3' splice sites in a polyA tail length-dependent manner; PABPN1 depletion induces retention of introns with weak 3' splice sites. Tethering PABPN1 to non-polyadenylated transcripts also promotes splicing, demonstrating a direct role. PABPN1 recruits RBM26/27 to promote splicing by interacting with the coiled-coil and RRM domain of RBM27, as established by TurboID-MS interactome analysis.","method":"PABPN1 depletion, RNA tethering assay, TurboID proximity labeling mass spectrometry, Co-IP with RBM27, splicing assays in HeLa and mouse cells","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — tethering assay + TurboID-MS + Co-IP with domain mapping, multiple orthogonal methods in two species, single lab","pmids":["37661812"],"is_preprint":false},{"year":2023,"finding":"The RNA-binding protein ZC3H11A interacts specifically with PABPN1 and requires PABPN1 for its localization into nuclear speckles; ZC3H11A uses the same zinc finger motifs to interact with both PABPN1 and viral mRNA. Lack of ZC3H11A alters polyadenylation of HAdV-5 capsid mRNA.","method":"ZC3H11A protein interactome (mass spectrometry), co-immunoprecipitation, nuclear speckle localization assay, viral mRNA polyadenylation analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP with functional localization and polyadenylation readout, single lab, multiple orthogonal methods","pmids":["37356722"],"is_preprint":false},{"year":2023,"finding":"PABPN1 liquid-liquid phase separation (LLPS) is disrupted by interaction of SNRPD2 with the glutamic-proline (EP) domain of PABPN1 in colorectal cancer; disruption of PABPN1 LLPS attenuates repression of proximal poly(A) sites, leading to shortened 3' UTR of CTNNBIP1 that promotes cell proliferation and migration.","method":"PABPN1 phase separation assay, Co-IP identifying SNRPD2-PABPN1 interaction (EP domain), APA analysis, cell proliferation and migration assays","journal":"Science China. Life sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — domain-specific Co-IP with phase separation functional assay and APA readout, single lab, multiple orthogonal methods","pmids":["38811444"],"is_preprint":false},{"year":2023,"finding":"PABPN1 aggregation is driven by both Ala stretch expansion and poly(A)-RNA binding: Ala expansion controls PABPN1 mobility in nuclear speckles and leads to aggregation; poly(A) nucleotide is essential for early-stage condensation facilitating speckle formation and transition to solid-like aggregates. PABPN1 aggregates sequester CFIm25 in an mRNA-dependent manner, impairing CFIm25 function in alternative polyadenylation.","method":"FRAP/live imaging in nuclear speckles, poly(A) RNA binding assay, CFIm25 co-localization and function assay, APA analysis","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — FRAP with RNA-binding assay and functional APA readout, single lab, multiple orthogonal methods","pmids":["37422193"],"is_preprint":false},{"year":2024,"finding":"PABPN1 is phosphorylated by mitotic kinases at four specific sites during mitosis; phospho-inhibitory mutations decrease cell proliferation and cause widespread poly(A) tail lengthening, while phospho-mimetic mutations result in shorter poly(A) tails with increased non-A nucleotides, increased transcription, and reduced stability of a distinct mRNA cohort. Phosphorylation thus remodels poly(A) tails and increases mRNA turnover to reset gene expression programs across the cell cycle.","method":"Stable cell lines with point mutations at phosphorylation sites, long-read sequencing for poly(A) tail length, TimeLapse-seq for mRNA synthesis and decay, cell proliferation assay","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 / Strong — site-specific mutagenesis with long-read sequencing and TimeLapse-seq providing mechanistic detail on poly(A) tail dynamics, single lab, multiple orthogonal high-resolution methods","pmids":["38943343"],"is_preprint":false},{"year":2025,"finding":"QKI promotes PABPN1 liquid-liquid phase separation (LLPS) in colorectal cancer cells; QKI is downregulated and loses nuclear localization in colorectal cancer, reducing PABPN1 phase separation and thereby promoting alternative polyadenylation, cell proliferation, and migration. Identified via CRISPR/BiFC/FACS screen.","method":"CRISPR/Cas9-based screening with bimolecular fluorescence complementation (BiFC) and FACS, QKI knockdown/overexpression, APA analysis, cell proliferation and migration assays","journal":"Protein & cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR screen with BiFC readout plus functional validation, single lab, multiple orthogonal methods","pmids":["40052530"],"is_preprint":false}],"current_model":"PABPN1 is a nuclear poly(A)-binding protein that stimulates poly(A) polymerase and controls poly(A) tail length, regulates alternative polyadenylation site selection (suppressing proximal sites), promotes post-polyadenylation splicing of terminal introns via poly(A) tail-dependent recruitment of splicing factors (including RBM26/27), negatively autoregulates its own expression via intron retention coupled to nuclear exosome decay, undergoes mitotic kinase phosphorylation that remodels poly(A) tails to reset transcriptome dynamics across the cell cycle, forms liquid-liquid phase separation condensates (nuclear speckles/NPADs) driven by its N-terminal disordered domain and RNA-binding activity, has an unforeseen cytoplasmic function in recruiting DIS3L2 to uridylated maternal mRNAs for ZGA-dependent decay in embryos, interacts with MATR3, hnRNP A1/A/B, ZC3H11A, ARIH2, and mitochondrial TIM23 complex, and exerts anti-apoptotic activity through XIAP translation regulation; disease-causing polyalanine expansions promote aggregation from nuclear speckles in an RNA-dependent manner, sequestering CFIm25 and other factors while depleting functional soluble PABPN1, with soluble expanded protein (not aggregates) being the primary toxic species."},"narrative":{"mechanistic_narrative":"PABPN1 is a nuclear poly(A)-binding protein that governs the maturation, fate, and length control of polyadenylated transcripts through its RNA-binding and poly(A) polymerase-stimulatory functions [PMID:25896913, PMID:36306357]. It is recruited cotranscriptionally to nascent mRNPs and remains associated through nuclear export [PMID:12749861, PMID:19336419], and controls 3'-end processing by suppressing proximal polyadenylation sites and biasing toward distal site usage [PMID:27152426, PMID:37422193]. Beyond tail-length control, PABPN1 couples polyadenylation to splicing of terminal introns bearing weak 3' splice sites in a poly(A) tail-dependent manner, acting directly by recruiting the splicing factors RBM26/RBM27 [PMID:37661812], and partners with MATR3 to coordinate alternative polyadenylation, intron retention, paraspeckle function, and A-to-I editing in muscle [PMID:28977530]. PABPN1 negatively autoregulates its own expression by binding an adenosine-rich element in its 3' UTR, promoting terminal-intron retention and nuclear exosome-mediated clearance of its pre-mRNA [PMID:25963658]. It forms liquid-liquid phase-separated nuclear poly(A) domains/speckles driven by its N-terminal disordered domain and RNA binding, a property essential for transcript stability and 3'UTR isoform formation in oocytes, with Pabpn1-null mice being sterile [PMID:36306357]. Mitotic phosphorylation at four sites remodels poly(A) tails and tunes mRNA turnover to reset gene expression across the cell cycle [PMID:38943343]. A cytoplasmic role has also been established whereby PABPN1 docks on 3'-uridylated maternal transcripts downstream of TUT4/7 and recruits the exoribonuclease DIS3L2 to drive zygotic genome activation-dependent maternal mRNA decay [PMID:34904664]. PABPN1 additionally exerts an anti-apoptotic activity by regulating XIAP translation [PMID:18178579]. Disease-causing N-terminal polyalanine expansions cause oculopharyngeal muscular dystrophy: expanded PABPN1 forms amyloid-like, RNA-dependent nuclear aggregates [PMID:14627730, PMID:37422193] that sequester partners including CFIm25 and hnRNP A1 [PMID:12945950, PMID:37422193], yet OPMD toxicity depends on the intrinsic RNA-binding function of PABPN1 rather than the polyalanine tract alone, and soluble expanded protein, not the insoluble aggregates, is the primary toxic species [PMID:16642034, PMID:17418585].","teleology":[{"year":2001,"claim":"Established that PABPN1 oligomerization domains drive the nuclear aggregation seen with polyalanine expansion and that aggregation is mechanistically linked to cell death.","evidence":"Deletion mutagenesis with aggregation and cell-death readouts in COS-7 cells","pmids":["11689481"],"confidence":"Medium","gaps":["Did not resolve whether aggregates themselves or soluble species are toxic","No structural basis for oligomerization"]},{"year":2003,"claim":"Placed PABPN1 on the cotranscriptional mRNP, showing it loads near transcription start and accompanies mRNP to the nuclear pore, framing it as an early and persistent mRNP factor.","evidence":"Cryo-immunoelectron microscopy of Balbiani ring mRNP in Chironomus tentans","pmids":["12749861"],"confidence":"Medium","gaps":["Single insect model system","Does not define the molecular trigger for displacement at the pore"]},{"year":2003,"claim":"Identified hnRNP A1/A/B as PABPN1 partners and showed they are co-sequestered into mutant aggregates and patient inclusions, linking aggregation to partner depletion.","evidence":"Yeast two-hybrid, GST pull-down, Co-IP, and immunofluorescence in cells and OPMD muscle","pmids":["12945950"],"confidence":"Medium","gaps":["Functional consequence of hnRNP sequestration not quantified","Direct interaction surface not mapped"]},{"year":2003,"claim":"Demonstrated biophysically that expanded polyalanine drives amyloid-like fibril formation with seeding behavior, providing a structural model for OPMD aggregation.","evidence":"In vitro recombinant protein fibrillation and structural/seeding assays","pmids":["14627730"],"confidence":"Medium","gaps":["In vitro only","Relationship of fibrils to cellular toxicity unresolved"]},{"year":2005,"claim":"Showed wild-type PABPN1 is intrinsically aggregation-prone and that inclusions are dynamic rather than irreversible, reframing aggregates as exchangeable reservoirs.","evidence":"FRAP and domain-deletion analysis in HeLa and C2 cells","pmids":["15811916"],"confidence":"Medium","gaps":["Does not establish whether dynamic exchange is protective or pathogenic","PAP-stimulation domain requirement not mechanistically dissected"]},{"year":2005,"claim":"Implicated HSP70/HSC70 chaperones in aggregate handling and showed pharmacological HSP70 induction reduces aggregate burden and cell death, identifying a tractable modifier.","evidence":"Pharmacological heat-shock induction with microscopy, solubility, and cell-death assays in HeLa","pmids":["16239242"],"confidence":"Medium","gaps":["Cell-based only; no in vivo validation","Off-target effects of inducers not excluded"]},{"year":2006,"claim":"Established that OPMD muscle degeneration requires the RNA-binding function of PABPN1, not the polyalanine tract per se, redefining the disease as a property of PABPN1 function.","evidence":"Domain-specific mutants in a Drosophila OPMD model","pmids":["16642034"],"confidence":"Medium","gaps":["Specific RNA targets driving degeneration not identified","Drosophila model may not capture all human muscle pathology"]},{"year":2007,"claim":"Resolved the toxic-species question by showing soluble expanded PABPN1, not insoluble aggregates, is the primary toxic entity.","evidence":"Live microscopy and aggregate-disruption experiments with cell-death readout in a cellular OPMD model","pmids":["17418585"],"confidence":"Medium","gaps":["Molecular basis of soluble-species toxicity not defined","Single cellular model"]},{"year":2008,"claim":"Defined an anti-apoptotic function for wild-type PABPN1 through regulation of XIAP translation, partially lost in the mutant, linking PABPN1 dosage to cell survival.","evidence":"Overexpression/knockdown in cell and mouse models with XIAP and apoptosis readouts","pmids":["18178579"],"confidence":"Medium","gaps":["Mechanism of XIAP translational control not detailed","Relevance to muscle pathology not established"]},{"year":2008,"claim":"Identified the SIRT1/AMPK/FoxO axis as a genetic and pharmacological modifier of mutant PABPN1 muscle toxicity.","evidence":"C. elegans genetic epistasis plus sirtinol/resveratrol treatment of mammalian cells","pmids":["18397876"],"confidence":"Medium","gaps":["Direct molecular link between SIRT1 and PABPN1 not established here","Cross-species relevance uncertain"]},{"year":2009,"claim":"Showed expanded PABPN1 preferentially recruits Hsp70 and type-I arginine methyltransferases (PRMT1/PRMT3), tying conformational change to altered partner binding.","evidence":"Pull-down, patient-muscle immunofluorescence, and molecular simulation","pmids":["19641605"],"confidence":"Medium","gaps":["Functional consequence of altered PRMT interaction untested","Simulation-based conformational claim not experimentally confirmed"]},{"year":2009,"claim":"Demonstrated via the fission yeast ortholog Pab2 that nuclear poly(A)-binding proteins are recruited cotranscriptionally ahead of canonical 3'-processing factors and persist on polysomes.","evidence":"RNase-sensitive ChIP, TAP-MS, and polysome fractionation in S. pombe","pmids":["19336419"],"confidence":"Medium","gaps":["Ortholog-based; human conservation of polysome association not shown","Recruitment mechanism not defined"]},{"year":2013,"claim":"Established a Pab2/exosome pathway for nuclear pre-mRNA decay opposed by Nab2, defining poly(A)-binding-protein competition as a decay-versus-stability switch.","evidence":"Genetic epistasis and RNA decay assays in S. pombe","pmids":["24081329"],"confidence":"Medium","gaps":["Ortholog system","Human equivalents of the competition not directly tested here"]},{"year":2013,"claim":"Mapped a PY-NLS/Kap104 import route for Pab2 while showing human PABPN1 uses an alternative/redundant import pathway, distinguishing nuclear targeting mechanisms.","evidence":"NLS mutagenesis, receptor-binding, and nuclear localization assays across yeast and human","pmids":["23279110"],"confidence":"Medium","gaps":["Human import receptor not identified","Redundancy not mapped"]},{"year":2015,"claim":"Defined PABPN1 negative autoregulation: it binds an A-rich element in its own 3' UTR to drive terminal-intron retention and exosome-mediated clearance, establishing dosage homeostasis.","evidence":"Dosage manipulation, spliced/unspliced ratio measurement, exosome knockdown, RNA-binding analysis","pmids":["25963658"],"confidence":"High","gaps":["Quantitative thresholds of the feedback loop not defined","In vivo physiological role of autoregulation untested"]},{"year":2015,"claim":"Showed PABPN1 and PAP cooperate to promote excision of introns removed only after polyadenylation, requiring both RNA-binding and PAP-stimulatory functions and impaired by alanine expansion.","evidence":"RNAi depletion, splicing assays, domain mutants, and exosome assays","pmids":["25896913"],"confidence":"Medium","gaps":["Splicing factors recruited not yet identified at this stage","Genome-wide scope not quantified"]},{"year":2015,"claim":"Demonstrated PABPN1 suppresses TDP-43 pathology by promoting its degradation and restoring solubility/localization, extending PABPN1 function to proteostasis of an aggregation-prone RBP.","evidence":"Overexpression/knockdown in cells and Drosophila with solubility, stress-granule, and localization readouts","pmids":["26130692"],"confidence":"Medium","gaps":["Mechanism of TDP-43 clearance not defined","Direct vs indirect effect unresolved"]},{"year":2016,"claim":"Linked PABPN1 dosage to muscle physiology in vivo: reduced PABPN1 shifts toward proximal poly(A) sites, upregulating Atrogin-1 and causing myofiber atrophy.","evidence":"AAV-shRNA knockdown in mouse TA muscle with poly(A) site, expression, and histological analyses","pmids":["27152426"],"confidence":"Medium","gaps":["Causal chain from APA shift to atrophy not fully dissected","Single muscle context"]},{"year":2017,"claim":"Identified MATR3 as a PABPN1 partner in skeletal muscle and showed the pair jointly regulates APA, intron retention, paraspeckles, Neat1, and RNA editing.","evidence":"Co-IP/MS, RNAi, APA, paraspeckle, and RNA-editing assays in muscle cells","pmids":["28977530"],"confidence":"High","gaps":["Division of labor between PABPN1 and MATR3 on specific targets unresolved","Interaction interface not mapped"]},{"year":2019,"claim":"Showed PABPN1 controls SIRT1 mRNA via APA, connecting the earlier SIRT1 modifier genetics to a direct regulatory mechanism in muscle wasting.","evidence":"Multi-omics and sirtinol pharmacological rescue in shPAB mouse muscle","pmids":["30739015"],"confidence":"Medium","gaps":["Acetylome targets driving wasting not pinpointed","Feedback between SIRT1 and PABPN1 not fully closed"]},{"year":2019,"claim":"Reported expanded PABPN1 accumulation in mitochondria and interaction with the TIM23 import complex, with OXPHOS deficits, extending pathology beyond the nucleus.","evidence":"Mitochondrial fractionation, TIM23 Co-IP, and patient/mouse tissue analysis","pmids":["30894671"],"confidence":"Medium","gaps":["Mechanism of mitochondrial targeting unclear","Causal contribution to OPMD pathology not established"]},{"year":2020,"claim":"Extended PABPN1 translational control to p63α via eIF4E/eIF4G modulation and APA of p63γ, embedding it in a keratinocyte-differentiation feedback loop.","evidence":"siRNA knockdown, APA, eIF4E/eIF4G Co-IP, ΔNp63α rescue, differentiation assays","pmids":["32243883"],"confidence":"Medium","gaps":["Direct vs indirect effect on initiation-factor binding unresolved","Single tissue context"]},{"year":2022,"claim":"Established that PABPN1 drives liquid-liquid phase separation into nuclear poly(A) domains essential for oocyte transcript stability and 3'UTR isoform formation, with knockout causing sterility.","evidence":"Pabpn1 knockout mice, live phase-separation imaging, domain deletion, RNA-seq, and fertility assays","pmids":["36306357"],"confidence":"High","gaps":["Composition and regulation of NPADs incompletely defined","Link between condensate formation and specific RNA fates partial"]},{"year":2022,"claim":"Revealed an unforeseen cytoplasmic function: PABPN1 docks on 3'-uridylated maternal mRNAs downstream of TUT4/7 and recruits DIS3L2 for ZGA-dependent decay, with knockout embryos arresting at morula.","evidence":"Pabpn1 knockout mice, RIP, DIS3L2 Co-IP, and maternal-mRNA decay RNA-seq","pmids":["34904664"],"confidence":"High","gaps":["How nuclear vs cytoplasmic PABPN1 pools are partitioned unknown","Structural basis of uridyl-transcript recognition not defined"]},{"year":2023,"claim":"Identified the direct splicing mechanism: PABPN1 promotes excision of weak-3'SS last introns in a poly(A) tail-dependent manner by recruiting RBM26/RBM27, mapping the recruitment to RBM27 domains.","evidence":"Depletion, RNA tethering, TurboID-MS, and RBM27 Co-IP/domain mapping in HeLa and mouse cells","pmids":["37661812"],"confidence":"High","gaps":["How RBM26/27 execute splicing downstream not detailed","Genome-wide intron selectivity rules incomplete"]},{"year":2023,"claim":"Showed ZC3H11A requires PABPN1 for nuclear speckle localization and uses shared zinc fingers for PABPN1 and viral mRNA binding, linking PABPN1 to viral mRNA polyadenylation.","evidence":"Interactome MS, Co-IP, speckle localization, and viral mRNA polyadenylation analysis","pmids":["37356722"],"confidence":"Medium","gaps":["Functional role of ZC3H11A–PABPN1 complex in host mRNA processing unclear","Competition between viral and host RNA not quantified"]},{"year":2023,"claim":"Dissected PABPN1 aggregation as driven by both alanine expansion (controlling speckle mobility) and poly(A)-RNA (essential for condensation), with aggregates sequestering CFIm25 to impair APA.","evidence":"FRAP, poly(A) RNA binding, CFIm25 co-localization/function, and APA assays","pmids":["37422193"],"confidence":"Medium","gaps":["Quantitative relationship between sequestration and APA defects partial","Reversibility of solid-like transition not tested"]},{"year":2023,"claim":"Showed SNRPD2 binds the EP domain of PABPN1 to disrupt its LLPS in colorectal cancer, de-repressing proximal poly(A) sites and shortening CTNNBIP1 3'UTR to promote tumor phenotypes.","evidence":"Phase-separation assays, domain-specific Co-IP, APA, and proliferation/migration assays","pmids":["38811444"],"confidence":"Medium","gaps":["Generality beyond CTNNBIP1 not established","In vivo tumor relevance not tested"]},{"year":2024,"claim":"Established cell-cycle control of PABPN1: mitotic phosphorylation at four sites remodels poly(A) tails and tunes mRNA synthesis/decay to reset transcriptome dynamics.","evidence":"Phospho-site mutants with long-read poly(A) sequencing, TimeLapse-seq, and proliferation assays","pmids":["38943343"],"confidence":"High","gaps":["Identity of the responsible mitotic kinases not pinned down","Specific affected mRNA cohorts incompletely characterized"]},{"year":2025,"claim":"Identified QKI as a positive regulator of PABPN1 LLPS, with its loss in colorectal cancer reducing phase separation and shifting APA toward pro-tumor isoforms.","evidence":"CRISPR/BiFC/FACS screen with QKI manipulation and APA/proliferation/migration assays","pmids":["40052530"],"confidence":"Medium","gaps":["Mechanism by which QKI promotes condensation unclear","Therapeutic relevance untested"]},{"year":null,"claim":"How nuclear and cytoplasmic PABPN1 pools are spatially partitioned and switched between poly(A)-tail control, condensate formation, splicing, and DIS3L2-dependent decay remains undefined.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model integrating RNA binding, LLPS, and partner recruitment","Mitotic kinases and human nuclear import receptor unidentified","Determinants of target selectivity across distinct functions unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[16,17,24,26,29]},{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[17,26,30]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[17,25,26]},{"term_id":"GO:0045182","term_label":"translation regulator activity","supporting_discovery_ids":[8,23]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[14,16,24]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[24,27,29]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[25]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[22]}],"pathway":[{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[16,17,25,26,30]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[1,11,19]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[3,6,7,29]},{"term_id":"R-HSA-1474165","term_label":"Reproduction","supporting_discovery_ids":[24,25]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[30]}],"complexes":["nuclear speckles / nuclear poly(A) domains (NPADs)"],"partners":["MATR3","RBM27","RBM26","ZC3H11A","DIS3L2","HNRNPA1","SNRPD2","QKI"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q86U42","full_name":"Polyadenylate-binding protein 2","aliases":["Nuclear poly(A)-binding protein 1","Poly(A)-binding protein II","PABII","Polyadenylate-binding nuclear protein 1"],"length_aa":306,"mass_kda":32.7,"function":"Involved in the 3'-end formation of mRNA precursors (pre-mRNA) by the addition of a poly(A) tail of 200-250 nt to the upstream cleavage product (By similarity). Stimulates poly(A) polymerase (PAPOLA) conferring processivity on the poly(A) tail elongation reaction and also controls the poly(A) tail length (By similarity). Increases the affinity of poly(A) polymerase for RNA (By similarity). Is also present at various stages of mRNA metabolism including nucleocytoplasmic trafficking and nonsense-mediated decay (NMD) of mRNA. Cooperates with SKIP to synergistically activate E-box-mediated transcription through MYOD1 and may regulate the expression of muscle-specific genes (PubMed:11371506). Binds to poly(A) and to poly(G) with high affinity (By similarity). May protect the poly(A) tail from degradation (By similarity). Subunit of the trimeric poly(A) tail exosome targeting (PAXT) complex, a complex that directs a subset of long and polyadenylated poly(A) RNAs for exosomal degradation. The RNA exosome is fundamental for the degradation of RNA in eukaryotic nuclei. Substrate targeting is facilitated by its cofactor MTREX, which links to RNA-binding protein adapters (PubMed:27871484)","subcellular_location":"Nucleus; Cytoplasm; Nucleus speckle","url":"https://www.uniprot.org/uniprotkb/Q86U42/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/PABPN1","classification":"Common Essential","n_dependent_lines":1205,"n_total_lines":1208,"dependency_fraction":0.9975165562913907},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"EMC9","stoichiometry":4.0},{"gene":"RBM33","stoichiometry":4.0},{"gene":"ATG13","stoichiometry":0.2},{"gene":"CPSF6","stoichiometry":0.2},{"gene":"DDX21","stoichiometry":0.2},{"gene":"DHX9","stoichiometry":0.2},{"gene":"ENY2","stoichiometry":0.2},{"gene":"HNRNPL","stoichiometry":0.2},{"gene":"MAP4","stoichiometry":0.2},{"gene":"NCAPH","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/PABPN1","total_profiled":1310},"omim":[{"mim_id":"621397","title":"PABPN1-LIKE, CYTOPLASMIC; PABPN1L","url":"https://www.omim.org/entry/621397"},{"mim_id":"620956","title":"ZINC FINGER C3H1 DOMAIN-CONTAINING PROTEIN; ZFC3H1","url":"https://www.omim.org/entry/620956"},{"mim_id":"618640","title":"ZINC FINGER CCCH DOMAIN-CONTAINING PROTEIN 3; ZC3H3","url":"https://www.omim.org/entry/618640"},{"mim_id":"602279","title":"POLYADENYLATE-BINDING PROTEIN, NUCLEAR, 1; PABPN1","url":"https://www.omim.org/entry/602279"},{"mim_id":"164310","title":"OCULOPHARYNGODISTAL MYOPATHY 1; OPDM1","url":"https://www.omim.org/entry/164310"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Nuclear speckles","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/PABPN1"},"hgnc":{"alias_symbol":["PAB2"],"prev_symbol":["OPMD","PABP2"]},"alphafold":{"accession":"Q86U42","domains":[{"cath_id":"3.30.70.330","chopping":"173-245","consensus_level":"high","plddt":94.6021,"start":173,"end":245}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q86U42","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q86U42-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q86U42-F1-predicted_aligned_error_v6.png","plddt_mean":67.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PABPN1","jax_strain_url":"https://www.jax.org/strain/search?query=PABPN1"},"sequence":{"accession":"Q86U42","fasta_url":"https://rest.uniprot.org/uniprotkb/Q86U42.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q86U42/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q86U42"}},"corpus_meta":[{"pmid":"28080204","id":"PMC_28080204","title":"Identification of HuR target circular RNAs uncovers suppression of PABPN1 translation by CircPABPN1.","date":"2017","source":"RNA biology","url":"https://pubmed.ncbi.nlm.nih.gov/28080204","citation_count":704,"is_preprint":false},{"pmid":"15817779","id":"PMC_15817779","title":"The MexGHI-OpmD multidrug efflux pump controls growth, antibiotic susceptibility and virulence in Pseudomonas aeruginosa via 4-quinolone-dependent cell-to-cell communication.","date":"2005","source":"Microbiology (Reading, England)","url":"https://pubmed.ncbi.nlm.nih.gov/15817779","citation_count":170,"is_preprint":false},{"pmid":"12177331","id":"PMC_12177331","title":"Characterization of a new efflux pump, MexGHI-OpmD, from Pseudomonas aeruginosa that confers resistance to vanadium.","date":"2002","source":"Microbiology (Reading, England)","url":"https://pubmed.ncbi.nlm.nih.gov/12177331","citation_count":142,"is_preprint":false},{"pmid":"11689481","id":"PMC_11689481","title":"Oligomerization of polyalanine expanded PABPN1 facilitates nuclear protein aggregation that is associated with cell death.","date":"2001","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11689481","citation_count":101,"is_preprint":false},{"pmid":"23601051","id":"PMC_23601051","title":"PABPN1: molecular function and muscle disease.","date":"2013","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/23601051","citation_count":97,"is_preprint":false},{"pmid":"16642034","id":"PMC_16642034","title":"A Drosophila model of oculopharyngeal muscular dystrophy reveals intrinsic toxicity of PABPN1.","date":"2006","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/16642034","citation_count":76,"is_preprint":false},{"pmid":"19609631","id":"PMC_19609631","title":"Bortezomib induces the formation of nuclear poly(A) RNA granules enriched in Sam68 and PABPN1 in sensory ganglia neurons.","date":"2009","source":"Neurotoxicity research","url":"https://pubmed.ncbi.nlm.nih.gov/19609631","citation_count":67,"is_preprint":false},{"pmid":"12937010","id":"PMC_12937010","title":"Functional cloning and characterization of a multidrug efflux pump, mexHI-opmD, from a Pseudomonas aeruginosa mutant.","date":"2003","source":"Antimicrobial agents and chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/12937010","citation_count":67,"is_preprint":false},{"pmid":"28977530","id":"PMC_28977530","title":"Nuclear poly(A) binding protein 1 (PABPN1) and Matrin3 interact in muscle cells and regulate RNA processing.","date":"2017","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/28977530","citation_count":62,"is_preprint":false},{"pmid":"25963658","id":"PMC_25963658","title":"Regulated Intron Retention and Nuclear Pre-mRNA Decay Contribute to PABPN1 Autoregulation.","date":"2015","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/25963658","citation_count":61,"is_preprint":false},{"pmid":"15811916","id":"PMC_15811916","title":"In vivo aggregation properties of the nuclear poly(A)-binding protein PABPN1.","date":"2005","source":"RNA (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/15811916","citation_count":59,"is_preprint":false},{"pmid":"15755682","id":"PMC_15755682","title":"PABPN1 overexpression leads to upregulation of genes encoding nuclear proteins that are sequestered in oculopharyngeal muscular dystrophy nuclear inclusions.","date":"2005","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/15755682","citation_count":58,"is_preprint":false},{"pmid":"28361972","id":"PMC_28361972","title":"PABPN1 gene therapy for oculopharyngeal muscular dystrophy.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28361972","citation_count":57,"is_preprint":false},{"pmid":"14645203","id":"PMC_14645203","title":"Myopathy phenotype in transgenic mice expressing mutated PABPN1 as a model of oculopharyngeal muscular dystrophy.","date":"2003","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14645203","citation_count":52,"is_preprint":false},{"pmid":"28011929","id":"PMC_28011929","title":"Correlation between PABPN1 genotype and disease severity in oculopharyngeal muscular dystrophy.","date":"2016","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/28011929","citation_count":51,"is_preprint":false},{"pmid":"18397876","id":"PMC_18397876","title":"Sirtuin inhibition protects from the polyalanine muscular dystrophy protein PABPN1.","date":"2008","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18397876","citation_count":51,"is_preprint":false},{"pmid":"31219352","id":"PMC_31219352","title":"Delivery of mesenchymal stem cells-derived extracellular vesicles with enriched miR-185 inhibits progression of OPMD.","date":"2019","source":"Artificial cells, nanomedicine, and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/31219352","citation_count":50,"is_preprint":false},{"pmid":"14627730","id":"PMC_14627730","title":"Trinucleotide expansions leading to an extended poly-L-alanine segment in the poly (A) binding protein PABPN1 cause fibril formation.","date":"2003","source":"Protein science : a publication of the Protein Society","url":"https://pubmed.ncbi.nlm.nih.gov/14627730","citation_count":49,"is_preprint":false},{"pmid":"23793615","id":"PMC_23793615","title":"A decline in PABPN1 induces progressive muscle weakness in oculopharyngeal muscle dystrophy and in muscle aging.","date":"2013","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/23793615","citation_count":47,"is_preprint":false},{"pmid":"12945950","id":"PMC_12945950","title":"HnRNP A1 and A/B interaction with PABPN1 in oculopharyngeal muscular dystrophy.","date":"2003","source":"The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques","url":"https://pubmed.ncbi.nlm.nih.gov/12945950","citation_count":46,"is_preprint":false},{"pmid":"12749861","id":"PMC_12749861","title":"Nuclear poly(A)-binding protein PABPN1 is associated with RNA polymerase II during transcription and accompanies the released transcript to the nuclear pore.","date":"2003","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/12749861","citation_count":43,"is_preprint":false},{"pmid":"16239242","id":"PMC_16239242","title":"Induction of HSP70 expression and recruitment of HSC70 and HSP70 in the nucleus reduce aggregation of a polyalanine expansion mutant of PABPN1 in HeLa cells.","date":"2005","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16239242","citation_count":43,"is_preprint":false},{"pmid":"28575395","id":"PMC_28575395","title":"Novel mouse models of oculopharyngeal muscular dystrophy (OPMD) reveal early onset mitochondrial defects and suggest loss of PABPN1 may contribute to pathology.","date":"2017","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/28575395","citation_count":40,"is_preprint":false},{"pmid":"15645184","id":"PMC_15645184","title":"Oculopharyngeal muscular dystrophy (OPMD): analysis of the PABPN1 gene expansion sequence in 86 patients reveals 13 different expansion types and further evidence for unequal recombination as the mutational mechanism.","date":"2005","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15645184","citation_count":40,"is_preprint":false},{"pmid":"21798095","id":"PMC_21798095","title":"Deregulation of the ubiquitin-proteasome system is the predominant molecular pathology in OPMD animal models and patients.","date":"2011","source":"Skeletal muscle","url":"https://pubmed.ncbi.nlm.nih.gov/21798095","citation_count":40,"is_preprint":false},{"pmid":"36306357","id":"PMC_36306357","title":"PABPN1 functions as a hub in the assembly of nuclear poly(A) domains that are essential for mouse oocyte development.","date":"2022","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/36306357","citation_count":39,"is_preprint":false},{"pmid":"25896913","id":"PMC_25896913","title":"Poly(A) Polymerase and the Nuclear Poly(A) Binding Protein, PABPN1, Coordinate the Splicing and Degradation of a Subset of Human Pre-mRNAs.","date":"2015","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/25896913","citation_count":39,"is_preprint":false},{"pmid":"18178579","id":"PMC_18178579","title":"Wild-type PABPN1 is anti-apoptotic and reduces toxicity of the oculopharyngeal muscular dystrophy mutation.","date":"2008","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18178579","citation_count":38,"is_preprint":false},{"pmid":"19641605","id":"PMC_19641605","title":"Hsp70 chaperones and type I PRMTs are sequestered at intranuclear inclusions caused by polyalanine expansions in PABPN1.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19641605","citation_count":38,"is_preprint":false},{"pmid":"21204267","id":"PMC_21204267","title":"Antiprion drugs 6-aminophenanthridine and guanabenz reduce PABPN1 toxicity and aggregation in oculopharyngeal muscular dystrophy.","date":"2011","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21204267","citation_count":37,"is_preprint":false},{"pmid":"15755680","id":"PMC_15755680","title":"Transgenic expression of an expanded (GCG)13 repeat PABPN1 leads to weakness and coordination defects in mice.","date":"2005","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/15755680","citation_count":37,"is_preprint":false},{"pmid":"27152426","id":"PMC_27152426","title":"PABPN1-Dependent mRNA Processing Induces Muscle Wasting.","date":"2016","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27152426","citation_count":36,"is_preprint":false},{"pmid":"34904664","id":"PMC_34904664","title":"Nuclear poly(A) binding protein 1 (PABPN1) mediates zygotic genome activation-dependent maternal mRNA clearance during mouse early embryonic development.","date":"2022","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/34904664","citation_count":34,"is_preprint":false},{"pmid":"17418585","id":"PMC_17418585","title":"Soluble expanded PABPN1 promotes cell death in oculopharyngeal muscular dystrophy.","date":"2007","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/17418585","citation_count":34,"is_preprint":false},{"pmid":"18367172","id":"PMC_18367172","title":"PABPN1 polyalanine tract deletion and long expansions modify its aggregation pattern and expression.","date":"2008","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/18367172","citation_count":33,"is_preprint":false},{"pmid":"31066242","id":"PMC_31066242","title":"Inhibition of myostatin improves muscle atrophy in oculopharyngeal muscular dystrophy (OPMD).","date":"2019","source":"Journal of cachexia, sarcopenia and muscle","url":"https://pubmed.ncbi.nlm.nih.gov/31066242","citation_count":33,"is_preprint":false},{"pmid":"24083404","id":"PMC_24083404","title":"Control of mRNA stability contributes to low levels of nuclear poly(A) binding protein 1 (PABPN1) in skeletal muscle.","date":"2013","source":"Skeletal muscle","url":"https://pubmed.ncbi.nlm.nih.gov/24083404","citation_count":33,"is_preprint":false},{"pmid":"35334101","id":"PMC_35334101","title":"Exosome-Mediated Transfer of miR-1323 from Cancer-Associated Fibroblasts Confers Radioresistance of C33A Cells by Targeting PABPN1 and Activating Wnt/β-Catenin Signaling Pathway in Cervical Cancer.","date":"2022","source":"Reproductive sciences (Thousand Oaks, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/35334101","citation_count":32,"is_preprint":false},{"pmid":"16648376","id":"PMC_16648376","title":"Oculopharyngeal muscular dystrophy: a point mutation which mimics the effect of the PABPN1 gene triplet repeat expansion mutation.","date":"2006","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16648376","citation_count":32,"is_preprint":false},{"pmid":"21854744","id":"PMC_21854744","title":"Modeling oculopharyngeal muscular dystrophy in myotube cultures reveals reduced accumulation of soluble mutant PABPN1 protein.","date":"2011","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21854744","citation_count":30,"is_preprint":false},{"pmid":"19336419","id":"PMC_19336419","title":"Cotranscriptional recruitment of the nuclear poly(A)-binding protein Pab2 to nascent transcripts and association with translating mRNPs.","date":"2009","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/19336419","citation_count":28,"is_preprint":false},{"pmid":"12445646","id":"PMC_12445646","title":"Characterization of outer membrane efflux proteins OpmE, OpmD and OpmB of Pseudomonas aeruginosa: molecular cloning and development of specific antisera.","date":"2002","source":"FEMS microbiology letters","url":"https://pubmed.ncbi.nlm.nih.gov/12445646","citation_count":28,"is_preprint":false},{"pmid":"24486325","id":"PMC_24486325","title":"A novel feed-forward loop between ARIH2 E3-ligase and PABPN1 regulates aging-associated muscle degeneration.","date":"2014","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24486325","citation_count":27,"is_preprint":false},{"pmid":"24081329","id":"PMC_24081329","title":"Poly(A) tail-mediated gene regulation by opposing roles of Nab2 and Pab2 nuclear poly(A)-binding proteins in pre-mRNA decay.","date":"2013","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/24081329","citation_count":25,"is_preprint":false},{"pmid":"12673802","id":"PMC_12673802","title":"Oculopharyngeal muscular dystrophy (OPMD) due to a small duplication in the PABPN1 gene.","date":"2003","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/12673802","citation_count":25,"is_preprint":false},{"pmid":"26130692","id":"PMC_26130692","title":"PABPN1 suppresses TDP-43 toxicity in ALS disease models.","date":"2015","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26130692","citation_count":24,"is_preprint":false},{"pmid":"37661812","id":"PMC_37661812","title":"The polyA tail facilitates splicing of last introns with weak 3' splice sites via PABPN1.","date":"2023","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/37661812","citation_count":23,"is_preprint":false},{"pmid":"23279110","id":"PMC_23279110","title":"A proline-tyrosine nuclear localization signal (PY-NLS) is required for the nuclear import of fission yeast PAB2, but not of human PABPN1.","date":"2013","source":"Traffic (Copenhagen, Denmark)","url":"https://pubmed.ncbi.nlm.nih.gov/23279110","citation_count":22,"is_preprint":false},{"pmid":"34453920","id":"PMC_34453920","title":"Propofol suppresses colorectal cancer development by the circ-PABPN1/miR-638/SRSF1 axis.","date":"2021","source":"Analytical biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34453920","citation_count":21,"is_preprint":false},{"pmid":"23300856","id":"PMC_23300856","title":"Depletion of nuclear poly(A) binding protein PABPN1 produces a compensatory response by cytoplasmic PABP4 and PABP5 in cultured human cells.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23300856","citation_count":21,"is_preprint":false},{"pmid":"21818414","id":"PMC_21818414","title":"Reversible aggregation of PABPN1 pre-inclusion structures.","date":"2011","source":"Nucleus (Austin, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/21818414","citation_count":19,"is_preprint":false},{"pmid":"27858728","id":"PMC_27858728","title":"PABPN1 (GCN)11 as a Dominant Allele in Oculopharyngeal Muscular Dystrophy -Consequences in Clinical Diagnosis and Genetic Counselling.","date":"2015","source":"Journal of neuromuscular diseases","url":"https://pubmed.ncbi.nlm.nih.gov/27858728","citation_count":18,"is_preprint":false},{"pmid":"18205394","id":"PMC_18205394","title":"Hofmeister salts and potential therapeutic compounds accelerate in vitro fibril formation of the N-terminal domain of PABPN1 containing a disease-causing alanine extension.","date":"2008","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18205394","citation_count":18,"is_preprint":false},{"pmid":"29939290","id":"PMC_29939290","title":"Post-transcriptional regulation of Pabpn1 by the RNA binding protein HuR.","date":"2018","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/29939290","citation_count":17,"is_preprint":false},{"pmid":"18255312","id":"PMC_18255312","title":"Nuclear compartmentalization and dynamics of the poly(A)-binding protein nuclear 1 (PABPN1) inclusions in supraoptic neurons under physiological and osmotic stress conditions.","date":"2007","source":"Molecular and cellular neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/18255312","citation_count":17,"is_preprint":false},{"pmid":"22641371","id":"PMC_22641371","title":"PABPN1 shuts down alternative poly(A) sites.","date":"2012","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/22641371","citation_count":17,"is_preprint":false},{"pmid":"33682567","id":"PMC_33682567","title":"Oral Potentially Malignant Disorders (OPMD): What is the clinical utility of dysplasia grade?","date":"2021","source":"Expert review of molecular diagnostics","url":"https://pubmed.ncbi.nlm.nih.gov/33682567","citation_count":16,"is_preprint":false},{"pmid":"22249111","id":"PMC_22249111","title":"Nuclear speckles are involved in nuclear aggregation of PABPN1 and in the pathophysiology of oculopharyngeal muscular dystrophy.","date":"2012","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/22249111","citation_count":16,"is_preprint":false},{"pmid":"16860991","id":"PMC_16860991","title":"The dynamism of PABPN1 nuclear inclusions during the cell cycle.","date":"2006","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/16860991","citation_count":15,"is_preprint":false},{"pmid":"28649424","id":"PMC_28649424","title":"An alanine expanded PABPN1 causes increased utilization of intronic polyadenylation sites.","date":"2017","source":"NPJ aging and mechanisms of disease","url":"https://pubmed.ncbi.nlm.nih.gov/28649424","citation_count":15,"is_preprint":false},{"pmid":"17229142","id":"PMC_17229142","title":"Effect of oculopharyngeal muscular dystrophy-associated extension of seven alanines on the fibrillation properties of the N-terminal domain of PABPN1.","date":"2007","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/17229142","citation_count":15,"is_preprint":false},{"pmid":"38811444","id":"PMC_38811444","title":"Disruption of PABPN1 phase separation by SNRPD2 drives colorectal cancer cell proliferation and migration through promoting alternative polyadenylation of CTNNBIP1.","date":"2024","source":"Science China. Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38811444","citation_count":14,"is_preprint":false},{"pmid":"15694141","id":"PMC_15694141","title":"(GCG)11 founder mutation in the PABPN1 gene of OPMD Uruguayan families.","date":"2005","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/15694141","citation_count":14,"is_preprint":false},{"pmid":"36879298","id":"PMC_36879298","title":"PABPN1 regulates mRNA alternative polyadenylation to inhibit bladder cancer progression.","date":"2023","source":"Cell & bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/36879298","citation_count":14,"is_preprint":false},{"pmid":"9084936","id":"PMC_9084936","title":"Oculopharyngeal muscular dystrophy (OPMD)--report and genetic studies of an Australian kindred.","date":"1997","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9084936","citation_count":14,"is_preprint":false},{"pmid":"30739015","id":"PMC_30739015","title":"Deacetylation Inhibition Reverses PABPN1-Dependent Muscle Wasting.","date":"2019","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/30739015","citation_count":13,"is_preprint":false},{"pmid":"35894779","id":"PMC_35894779","title":"Novel read-through fusion transcript Bcl2l2-Pabpn1 in glioblastoma cells.","date":"2022","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35894779","citation_count":13,"is_preprint":false},{"pmid":"22570486","id":"PMC_22570486","title":"Polyalanine-independent conformational conversion of nuclear poly(A)-binding protein 1 (PABPN1).","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22570486","citation_count":13,"is_preprint":false},{"pmid":"29088723","id":"PMC_29088723","title":"Dysfunctional transcripts are formed by alternative polyadenylation in OPMD.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29088723","citation_count":12,"is_preprint":false},{"pmid":"20227501","id":"PMC_20227501","title":"Cross-talk between canonical Wnt signaling and the sirtuin-FoxO longevity pathway to protect against muscular pathology induced by mutant PABPN1 expression in C. elegans.","date":"2010","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/20227501","citation_count":12,"is_preprint":false},{"pmid":"26527730","id":"PMC_26527730","title":"Automated design of hammerhead ribozymes and validation by targeting the PABPN1 gene transcript.","date":"2015","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/26527730","citation_count":12,"is_preprint":false},{"pmid":"17550990","id":"PMC_17550990","title":"Multiple mitochondrial DNA deletions in monozygotic twins with OPMD.","date":"2007","source":"Journal of neurology, neurosurgery, and psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/17550990","citation_count":12,"is_preprint":false},{"pmid":"32243883","id":"PMC_32243883","title":"PABPN1, a Target of p63, Modulates Keratinocyte Differentiation through Regulation of p63α mRNA Translation.","date":"2020","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/32243883","citation_count":11,"is_preprint":false},{"pmid":"22817818","id":"PMC_22817818","title":"Oculopharyngeal muscular dystrophy --an under-diagnosed disease in China? Report a China-born Chinese with PABPN1 mutation and epidemiology review of the literature.","date":"2012","source":"Journal of the Formosan Medical Association = Taiwan yi zhi","url":"https://pubmed.ncbi.nlm.nih.gov/22817818","citation_count":11,"is_preprint":false},{"pmid":"36657275","id":"PMC_36657275","title":"MiRNAs as non-invasive biomarkers in the serum of Oral Squamous Cell Carcinoma (OSCC) and Oral Potentially Malignant Disorder (OPMD) patients.","date":"2023","source":"Archives of oral biology","url":"https://pubmed.ncbi.nlm.nih.gov/36657275","citation_count":11,"is_preprint":false},{"pmid":"39160581","id":"PMC_39160581","title":"Areca nut-induced metabolic reprogramming and M2 differentiation promote OPMD malignant transformation.","date":"2024","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/39160581","citation_count":10,"is_preprint":false},{"pmid":"33533011","id":"PMC_33533011","title":"Anti-prion Drugs Targeting the Protein Folding Activity of the Ribosome Reduce PABPN1 Aggregation.","date":"2021","source":"Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/33533011","citation_count":10,"is_preprint":false},{"pmid":"36197469","id":"PMC_36197469","title":"Assessment of PABPN1 nuclear inclusions on a large cohort of patients and in a human xenograft model of oculopharyngeal muscular dystrophy.","date":"2022","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/36197469","citation_count":10,"is_preprint":false},{"pmid":"38213032","id":"PMC_38213032","title":"PABPN1 loss-of-function causes APA-shift in oculopharyngeal muscular dystrophy.","date":"2024","source":"HGG advances","url":"https://pubmed.ncbi.nlm.nih.gov/38213032","citation_count":9,"is_preprint":false},{"pmid":"30894671","id":"PMC_30894671","title":"Mitochondrial localization of PABPN1 in oculopharyngeal muscular dystrophy.","date":"2019","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/30894671","citation_count":9,"is_preprint":false},{"pmid":"34225694","id":"PMC_34225694","title":"A Japanese case of oculopharyngeal muscular dystrophy (OPMD) with PABPN1 c.35G > C; p.Gly12Ala point mutation.","date":"2021","source":"BMC neurology","url":"https://pubmed.ncbi.nlm.nih.gov/34225694","citation_count":9,"is_preprint":false},{"pmid":"21742497","id":"PMC_21742497","title":"Two cases of oculopharyngeal muscular dystrophy (OPMD) with the rare PABPN1 c.35G>C; p.Gly12Ala point mutation.","date":"2011","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/21742497","citation_count":9,"is_preprint":false},{"pmid":"15725589","id":"PMC_15725589","title":"Oculopharyngeal muscular dystrophy with PABPN1 mutation in a Chinese Malaysian woman.","date":"2005","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/15725589","citation_count":9,"is_preprint":false},{"pmid":"38244911","id":"PMC_38244911","title":"Dysregulation of RNA-Exosome machinery is directly linked to major cancer hallmarks in prostate cancer: Oncogenic role of PABPN1.","date":"2024","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/38244911","citation_count":8,"is_preprint":false},{"pmid":"33077830","id":"PMC_33077830","title":"Cytoskeletal disorganization underlies PABPN1-mediated myogenic disability.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33077830","citation_count":8,"is_preprint":false},{"pmid":"37452741","id":"PMC_37452741","title":"PABPN1 promotes clear cell renal cell carcinoma progression by suppressing the alternative polyadenylation of SGPL1 and CREG1.","date":"2023","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/37452741","citation_count":8,"is_preprint":false},{"pmid":"37356722","id":"PMC_37356722","title":"The RNA-binding protein ZC3H11A interacts with the nuclear poly(A)-binding protein PABPN1 and alters polyadenylation of viral transcripts.","date":"2023","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37356722","citation_count":8,"is_preprint":false},{"pmid":"31294444","id":"PMC_31294444","title":"Established PABPN1 intranuclear inclusions in OPMD muscle can be efficiently reversed by AAV-mediated knockdown and replacement of mutant expanded PABPN1.","date":"2019","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31294444","citation_count":8,"is_preprint":false},{"pmid":"27980005","id":"PMC_27980005","title":"Characterization of PABPN1 expansion mutations in a large cohort of Mexican patients with oculopharyngeal muscular dystrophy (OPMD).","date":"2016","source":"Journal of investigative medicine : the official publication of the American Federation for Clinical Research","url":"https://pubmed.ncbi.nlm.nih.gov/27980005","citation_count":8,"is_preprint":false},{"pmid":"18577654","id":"PMC_18577654","title":"Two different PABPN1 expanded alleles in a Mexican population with oculopharyngeal muscular dystrophy arising from independent founder effects.","date":"2008","source":"The British journal of ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/18577654","citation_count":8,"is_preprint":false},{"pmid":"38943343","id":"PMC_38943343","title":"Phosphorylation of the nuclear poly(A) binding protein (PABPN1) during mitosis protects mRNA from hyperadenylation and maintains transcriptome dynamics.","date":"2024","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/38943343","citation_count":6,"is_preprint":false},{"pmid":"28303574","id":"PMC_28303574","title":"Functional impact of an oculopharyngeal muscular dystrophy mutation in PABPN1.","date":"2017","source":"The Journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/28303574","citation_count":6,"is_preprint":false},{"pmid":"37422193","id":"PMC_37422193","title":"PABPN1 aggregation is driven by Ala expansion and poly(A)-RNA binding, leading to CFIm25 sequestration that impairs alternative polyadenylation.","date":"2023","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37422193","citation_count":6,"is_preprint":false},{"pmid":"37036407","id":"PMC_37036407","title":"Expression of Human Papillomavirus and the p16 Gene in Oral Potentially Malignant Disorders (OPMD): a Comparative Study With Oral Squamous Cell Carcinoma.","date":"2023","source":"Applied immunohistochemistry & molecular morphology : AIMM","url":"https://pubmed.ncbi.nlm.nih.gov/37036407","citation_count":6,"is_preprint":false},{"pmid":"20226184","id":"PMC_20226184","title":"Structural basis for a PABPN1 aggregation-preventing antibody fragment in OPMD.","date":"2010","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/20226184","citation_count":6,"is_preprint":false},{"pmid":"35327999","id":"PMC_35327999","title":"Characterization of a Read-through Fusion Transcript, BCL2L2-PABPN1, Involved in Porcine Adipogenesis.","date":"2022","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/35327999","citation_count":6,"is_preprint":false},{"pmid":"18358598","id":"PMC_18358598","title":"A case of rare recessive oculopharyngeal muscular dystrophy (OPMD) coexisting with hereditary neuropathy with liability to pressure palsies (HNPP).","date":"2008","source":"Clinical neurology and neurosurgery","url":"https://pubmed.ncbi.nlm.nih.gov/18358598","citation_count":6,"is_preprint":false},{"pmid":"18406354","id":"PMC_18406354","title":"Monitoring fibril formation of the N-terminal domain of PABPN1 carrying an alanine repeat by tryptophan fluorescence and real-time NMR.","date":"2008","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/18406354","citation_count":6,"is_preprint":false},{"pmid":"27281858","id":"PMC_27281858","title":"[Haplotype Analysis of Oculopharyngeal Muscular Dystrophy (OPMD) Locus in Yakutia].","date":"2016","source":"Genetika","url":"https://pubmed.ncbi.nlm.nih.gov/27281858","citation_count":5,"is_preprint":false},{"pmid":"40052530","id":"PMC_40052530","title":"BiFC and FACS-based CRISPR screening revealed that QKI promotes PABPN1 LLPS in colorectal cancer cells.","date":"2025","source":"Protein & cell","url":"https://pubmed.ncbi.nlm.nih.gov/40052530","citation_count":4,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48979,"output_tokens":8375,"usd":0.136281,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17967,"output_tokens":7950,"usd":0.144292,"stage2_stop_reason":"end_turn"},"total_usd":0.280573,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"PABPN1 oligomerization is mediated by two potential oligomerization domains (ODs) in the protein; deletion of 6-8 amino acids in either OD prevents nuclear protein aggregation induced by polyalanine-expanded PABPN1, and prevention of aggregation significantly reduces cell death in COS-7 cells expressing mutant PABPN1.\",\n      \"method\": \"Deletion mutagenesis, exogenous expression in COS-7 cells, immunofluorescence microscopy, cell death assay\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain deletion mutagenesis with functional readout (aggregation and cell death), single lab, two orthogonal methods\",\n      \"pmids\": [\"11689481\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"PABPN1 is associated with RNA polymerase II along the chromatin axis of the BR gene, suggesting it binds to the polymerase before, at, or shortly after the start of transcription; PABPN1 accompanies the released mRNP to the nuclear pore and is displaced from mRNPs during or shortly after passage through the nuclear pore.\",\n      \"method\": \"Cryo-immunoelectron microscopy on Chironomus tentans salivary gland Balbiani ring mRNP\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cryo-immunoelectron microscopy with spatial resolution, single lab, single method but high-resolution technique\",\n      \"pmids\": [\"12749861\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"PABPN1 interacts with hnRNP A1 and hnRNP A/B (identified by yeast two-hybrid screen and confirmed by GST pull-down and co-immunoprecipitation); when co-expressed with mutant PABPN1 in COS-7 cells, hnRNP A1 and A/B co-localize with mutant PABPN1 in insoluble intranuclear aggregates, and hnRNP A1 is sequestered in OPMD nuclear inclusions in patient muscle.\",\n      \"method\": \"Yeast two-hybrid screen, GST pull-down, co-immunoprecipitation, immunofluorescence in COS-7 cells and patient muscle\",\n      \"journal\": \"The Canadian journal of neurological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP and GST pull-down with cellular localization confirmation, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"12945950\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Expanded polyalanine in PABPN1 N-terminal domain drives fibril formation with amyloid-like characteristics (antiparallel beta-sheets) in vitro; the lag-phase of fibril formation is reduced by seeding, and expansion to maximal OPMD length increases alpha-helical structure preceding fibrillation.\",\n      \"method\": \"In vitro recombinant protein assay, structural analysis (amyloid characteristics), seeding experiments\",\n      \"journal\": \"Protein science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with structural analysis, single lab, multiple biophysical methods\",\n      \"pmids\": [\"14627730\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Normal (wild-type) PABPN1 is inherently aggregation-prone when exogenously expressed; protein domains required for stimulation of poly(A) polymerase are required for inclusion formation; FRAP experiments show both normal and expanded PABPN1 molecules move rapidly in and out of inclusions rather than being irreversibly sequestered.\",\n      \"method\": \"Exogenous expression in HeLa and C2 cells, domain deletion analysis, photobleaching (FRAP) experiments\",\n      \"journal\": \"RNA\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — live-cell FRAP and domain mutagenesis with functional readout, single lab, two orthogonal methods\",\n      \"pmids\": [\"15811916\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"HSC70 and HSP70 chaperones interact with and localize to PABPN1 intranuclear inclusions; pharmacological induction of HSP70 (by ZnSO4, 8-hydroxyquinoline, ibuprofen, or indomethacin) recruits HSP70 and HSC70 into the nucleus and significantly reduces mutant PABPN1 aggregate burden and concomitant cell death.\",\n      \"method\": \"Pharmacological induction of heat shock response, confocal microscopy, solubility assay, cell death assay in HeLa cells\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pharmacological agents with orthogonal readouts (microscopy and solubility), single lab\",\n      \"pmids\": [\"16239242\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"In a Drosophila model of OPMD, the RNA-binding domain of PABPN1 and its RNA-binding function are required for muscle degeneration, whereas the polyalanine tract is not absolutely required; this establishes that OPMD does not result purely from polyalanine toxicity but from an intrinsic property of PABPN1.\",\n      \"method\": \"Drosophila transgenic model, domain deletion/mutation analysis, muscle degeneration phenotype readout\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis via domain-specific mutants in an in vivo model, single lab, clear phenotypic readout\",\n      \"pmids\": [\"16642034\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Soluble forms of expanded PABPN1 (expPABPN1), not the insoluble nuclear aggregates, are the primary toxic species; interfering with large nuclear aggregate formation increases soluble expPABPN1 and significantly exacerbates cell death, as demonstrated by live microscopy.\",\n      \"method\": \"Live microscopy, aggregate disruption experiments, cell death assay in cellular OPMD model\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — live imaging with functional cell death readout, single lab, two orthogonal methods\",\n      \"pmids\": [\"17418585\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Wild-type PABPN1 exerts an anti-apoptotic function by regulating translation of X-linked inhibitor of apoptosis (XIAP) protein; overexpression of wild-type PABPN1 reduces mutant PABPN1 toxicity and protects cells from pro-apoptotic insults, while PABPN1 knockdown increases apoptotic susceptibility. This protective activity is partially lost for mutant PABPN1.\",\n      \"method\": \"Overexpression and knockdown in cell and mouse models, XIAP protein level measurement, apoptosis assay\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KD and OE with specific molecular target (XIAP), cell and mouse model validation, single lab\",\n      \"pmids\": [\"18178579\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Sirtuin SIRT1/sir-2.1 pathway and AMPK (aak-2) modulate mutant PABPN1 toxicity in muscle: increased sir-2.1 dosage exacerbates muscle pathology in a daf-16/FoxO- and aak-2/AMPK-dependent manner in C. elegans, while sir-2.1 null mutants are protective. SIRT1 inhibitor sirtinol promotes survival of mammalian cells expressing mutant PABPN1.\",\n      \"method\": \"C. elegans genetics (increased/null sir-2.1 dosage, double mutants), pharmacological treatment (sirtinol, resveratrol), mammalian cell survival assay\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis in C. elegans with pharmacological validation in mammalian cells, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"18397876\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Expanded PABPN1 preferentially binds Hsp70 chaperones and type I arginine methyltransferases (PRMT1 and PRMT3) compared to wild-type PABPN1; these proteins accumulate at intranuclear inclusions in OPMD patient muscle. Molecular simulations suggest polyalanine expansion transitions PABPN1 from disordered to stable helical conformation, altering these interactions.\",\n      \"method\": \"Pull-down assays, immunofluorescence in patient muscle, molecular simulation\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — pull-down with patient tissue validation, single lab, two orthogonal methods\",\n      \"pmids\": [\"19641605\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Fission yeast PABPN1 ortholog Pab2 is cotranscriptionally recruited to active genes via nascent mRNPs (demonstrated by RNase-sensitive ChIP), with recruitment preceding that of typical 3'-processing/polyadenylation factors; Pab2 also associates with polysomes, suggesting it remains associated with translated mRNPs after nuclear export.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP) with RNase treatment, tandem affinity purification coupled with mass spectrometry, polysome fractionation\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP with RNase control and TAP-MS, single lab, multiple orthogonal methods; fission yeast ortholog\",\n      \"pmids\": [\"19336419\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Full-length PABPN1 forms amyloid-like fibrils in vitro independently of the alanine segment; fibril formation kinetics and denaturation resistance differ from those of the N-terminal domain alone, and FTIR spectroscopy plus limited proteolysis indicate the C-terminal domain is involved in fibril formation.\",\n      \"method\": \"In vitro fibril formation assay, FTIR spectroscopy, limited proteolysis, chaotropic denaturant resistance\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with structural analysis (FTIR, proteolysis), single lab, multiple biophysical methods\",\n      \"pmids\": [\"22570486\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Fission yeast nuclear poly(A)-binding proteins Pab2 (PABPN1 ortholog) and Nab2 have opposing roles in posttranscriptional regulation: Pab2 promotes nuclear pre-mRNA decay via the nuclear exosome subunit Rrp6, while Nab2 impedes Pab2/Rrp6-mediated decay by competing with Pab2 for polyadenylated transcripts in the nucleus.\",\n      \"method\": \"Genetic epistasis (double mutants), RNA decay assays, northern blotting in S. pombe\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis with RNA decay assays in fission yeast, single lab, multiple orthogonal methods; S. pombe ortholog\",\n      \"pmids\": [\"24081329\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"A proline-tyrosine nuclear localization signal (PY-NLS) is necessary and sufficient for nuclear localization of fission yeast Pab2, functioning through Kap104 (Kapβ2 ortholog); however, neither a functional PY-NLS nor Kapβ2 activity are required for nuclear import of human PABPN1, indicating alternative or redundant import pathways exist for human PABPN1.\",\n      \"method\": \"NLS deletion/mutation analysis, nuclear localization assay, recombinant protein binding to Kap104, in vivo nuclear localization of human PABPN1\",\n      \"journal\": \"Traffic\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct nuclear localization experiments with domain mutagenesis and receptor binding assay, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"23279110\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ARIH2 E3 ubiquitin ligase regulates PABPN1 protein accumulation and aggregation; PABPN1 controls ARIH2 mRNA levels via proximal polyadenylation site usage, forming a feed-forward regulatory loop. Masking the proximal polyadenylation site in ARIH2 3' UTR using antisense oligonucleotides elevates both ARIH2 and PABPN1 expression and restores myogenic defects.\",\n      \"method\": \"Antisense oligonucleotide treatment, protein accumulation and aggregation assay, RNA expression analysis, myogenesis assay\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — antisense oligonucleotide functional intervention with multiple readouts, single lab\",\n      \"pmids\": [\"24486325\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PABPN1 negatively controls its own expression (autoregulation) by binding to an adenosine-rich region in its own 3' UTR, which promotes retention of the 3'-terminal intron and clearance of intron-retained pre-mRNAs by the nuclear exosome; increased PABPN1 dosage reduces the spliced/unspliced transcript ratio and decreases endogenous PABPN1 protein levels.\",\n      \"method\": \"PABPN1 dosage manipulation, spliced/unspliced RNA ratio measurement, nuclear exosome knockdown, RNA binding analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — mechanistic pathway (PABPN1 → intron retention → nuclear exosome decay) established with multiple orthogonal methods and rescue experiments, single lab\",\n      \"pmids\": [\"25963658\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PABPN1 and poly(A) polymerase (PAP) coordinate splicing of a subset of introns that are excised after polyadenylation; PABPN1 promotes intron excision specifically in the context of 3'-end polyadenylation (not when bound to internal A-tracts), requiring its RNA-binding function and PAP-stimulatory function. N-terminal alanine-expanded PABPN1 cannot fully rescue PABPN1 depletion effects on this pathway.\",\n      \"method\": \"PABPN1 depletion (RNAi), PAP depletion, splicing assays, RNA-binding domain mutant analysis, exosome assays\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain-specific mutant analysis combined with depletion and exosome assays, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"25896913\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PABPN1 suppresses TDP-43 toxicity; overexpression of full-length PABPN1 (but not a truncated form lacking the nuclear localization signal) promotes degradation of pathological TDP-43, restores normal TDP-43 solubility and nuclear localization, and facilitates removal of persistent stress granules. Reduced PABPN1 enhances TDP-43 pathological phenotypes and causes cytoplasmic mislocalization of TDP-43.\",\n      \"method\": \"Overexpression and knockdown in cell culture and Drosophila models, TDP-43 solubility fractionation, stress granule dynamics assay, nuclear localization analysis\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KD and OE with multiple orthogonal readouts in cell and Drosophila models, single lab\",\n      \"pmids\": [\"26130692\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Reduced PABPN1 levels in mouse tibialis anterior muscle cause consistent decline in distal polyadenylation site (PAS) utilization, leading to upregulation of Atrogin-1 (a key muscle atrophy regulator), reduced proteasomal gene expression and activity, and myofiber atrophy with extracellular matrix thickening.\",\n      \"method\": \"AAV-shRNA knockdown in mouse TA muscle, poly(A) site utilization analysis, gene expression profiling, proteasomal activity assay, histological analysis\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo KD with multiple molecular and histological readouts, single lab\",\n      \"pmids\": [\"27152426\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PABPN1 interacts with Matrin 3 (MATR3) in mouse skeletal muscle (identified by co-immunoprecipitation and mass spectrometry); together PABPN1 and MATR3 regulate alternative polyadenylation, intron retention, paraspeckle morphology and function, Neat1 lncRNA levels, and adenosine-to-inosine (A-to-I) RNA editing of Ctn RNA in muscle cells.\",\n      \"method\": \"Co-immunoprecipitation, mass spectrometry, RNAi knockdown, alternative polyadenylation assay, paraspeckle morphology analysis, RNA editing assay\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP/MS for interaction identification plus multiple functional readouts, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"28977530\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"PABPN1 regulates SIRT1 mRNA levels via alternative polyadenylation site utilization; reduced PABPN1 leads to elevated SIRT1 deacetylase activity, decreased protein acetylation, and muscle wasting. SIRT1 deacetylase inhibition by sirtinol increases PABPN1 levels and reverses muscle wasting.\",\n      \"method\": \"Transcriptome and proteome comparison, acetylome profiling, SIRT1 expression analysis, sirtinol pharmacological treatment in shPAB mouse muscles\",\n      \"journal\": \"iScience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multi-omics with pharmacological rescue in vivo, single lab\",\n      \"pmids\": [\"30739015\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Expanded PABPN1 accumulates in mitochondria and interacts with the TIM23 mitochondrial protein import complex; both wild-type (10-alanine) and expanded (18-alanine) PABPN1 accumulate in mitochondria, but the 18-alanine form decreases cell viability and induces aggresome formation. Reduced OXPHOS complex expression was detected in transgenic OPMD mouse muscle.\",\n      \"method\": \"Mitochondrial fractionation, co-immunoprecipitation with TIM23, immunofluorescence in patient muscle and mouse model, OXPHOS complex expression analysis\",\n      \"journal\": \"Laboratory investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — subcellular fractionation and Co-IP with in vivo validation in patient and mouse tissue, single lab\",\n      \"pmids\": [\"30894671\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PABPN1 is necessary for p63α mRNA translation by modulating binding of translation initiation factors eIF4E and eIF4G to p63α mRNA; PABPN1 deficiency also increases p63γ mRNA through alternative polyadenylation in coding sequence. p63α (especially ΔNp63α) regulates PABPN1 transcription, forming a feedback loop that controls keratinocyte differentiation.\",\n      \"method\": \"PABPN1 siRNA knockdown, APA analysis, translation initiation factor binding assay (eIF4E/eIF4G co-IP), ectopic ΔNp63α rescue, keratinocyte differentiation assay\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP of translation factors with functional rescue, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"32243883\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PABPN1 promotes the formation of nuclear poly(A) domains (NPADs) in mouse oocytes through liquid phase separation, driven by its N-terminal disordered domain and RNA-recognition motif; Pabpn1-null oocytes cannot form NPADs normally, have defects in transcript stability and long 3'UTR isoform formation, and Pabpn1-null mice are completely sterile with primary ovarian insufficiency.\",\n      \"method\": \"Pabpn1 knockout mouse model, live imaging of phase separation, domain deletion analysis, RNA-seq for 3'UTR isoform analysis, fertility assessment\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knockout mouse with domain analysis, phase separation imaging, and multiple functional readouts, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"36306357\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PABPN1 has a cytoplasmic function in zygotic genome activation (ZGA)-dependent maternal mRNA clearance; cytoplasmic PABPN1 docks on 3'-uridylated transcripts downstream of TUT4/TUT7 uridyltransferases and recruits 3'-5' exoribonuclease DIS3L2 to facilitate maternal mRNA decay. Pabpn1 knockout embryos arrest at the morula stage with failure to remove Z-decay maternal mRNAs.\",\n      \"method\": \"Pabpn1 knockout mouse, RNA immunoprecipitation, DIS3L2 co-immunoprecipitation, RNA-seq of maternal mRNA decay, developmental stage analysis\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knockout mouse with mechanistic pathway placement (TUT4/7 → PABPN1 → DIS3L2) and multiple orthogonal validations, single lab\",\n      \"pmids\": [\"34904664\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PABPN1 promotes splicing of last introns with weak 3' splice sites in a polyA tail length-dependent manner; PABPN1 depletion induces retention of introns with weak 3' splice sites. Tethering PABPN1 to non-polyadenylated transcripts also promotes splicing, demonstrating a direct role. PABPN1 recruits RBM26/27 to promote splicing by interacting with the coiled-coil and RRM domain of RBM27, as established by TurboID-MS interactome analysis.\",\n      \"method\": \"PABPN1 depletion, RNA tethering assay, TurboID proximity labeling mass spectrometry, Co-IP with RBM27, splicing assays in HeLa and mouse cells\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — tethering assay + TurboID-MS + Co-IP with domain mapping, multiple orthogonal methods in two species, single lab\",\n      \"pmids\": [\"37661812\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"The RNA-binding protein ZC3H11A interacts specifically with PABPN1 and requires PABPN1 for its localization into nuclear speckles; ZC3H11A uses the same zinc finger motifs to interact with both PABPN1 and viral mRNA. Lack of ZC3H11A alters polyadenylation of HAdV-5 capsid mRNA.\",\n      \"method\": \"ZC3H11A protein interactome (mass spectrometry), co-immunoprecipitation, nuclear speckle localization assay, viral mRNA polyadenylation analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP with functional localization and polyadenylation readout, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"37356722\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PABPN1 liquid-liquid phase separation (LLPS) is disrupted by interaction of SNRPD2 with the glutamic-proline (EP) domain of PABPN1 in colorectal cancer; disruption of PABPN1 LLPS attenuates repression of proximal poly(A) sites, leading to shortened 3' UTR of CTNNBIP1 that promotes cell proliferation and migration.\",\n      \"method\": \"PABPN1 phase separation assay, Co-IP identifying SNRPD2-PABPN1 interaction (EP domain), APA analysis, cell proliferation and migration assays\",\n      \"journal\": \"Science China. Life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — domain-specific Co-IP with phase separation functional assay and APA readout, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"38811444\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PABPN1 aggregation is driven by both Ala stretch expansion and poly(A)-RNA binding: Ala expansion controls PABPN1 mobility in nuclear speckles and leads to aggregation; poly(A) nucleotide is essential for early-stage condensation facilitating speckle formation and transition to solid-like aggregates. PABPN1 aggregates sequester CFIm25 in an mRNA-dependent manner, impairing CFIm25 function in alternative polyadenylation.\",\n      \"method\": \"FRAP/live imaging in nuclear speckles, poly(A) RNA binding assay, CFIm25 co-localization and function assay, APA analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — FRAP with RNA-binding assay and functional APA readout, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"37422193\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PABPN1 is phosphorylated by mitotic kinases at four specific sites during mitosis; phospho-inhibitory mutations decrease cell proliferation and cause widespread poly(A) tail lengthening, while phospho-mimetic mutations result in shorter poly(A) tails with increased non-A nucleotides, increased transcription, and reduced stability of a distinct mRNA cohort. Phosphorylation thus remodels poly(A) tails and increases mRNA turnover to reset gene expression programs across the cell cycle.\",\n      \"method\": \"Stable cell lines with point mutations at phosphorylation sites, long-read sequencing for poly(A) tail length, TimeLapse-seq for mRNA synthesis and decay, cell proliferation assay\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — site-specific mutagenesis with long-read sequencing and TimeLapse-seq providing mechanistic detail on poly(A) tail dynamics, single lab, multiple orthogonal high-resolution methods\",\n      \"pmids\": [\"38943343\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"QKI promotes PABPN1 liquid-liquid phase separation (LLPS) in colorectal cancer cells; QKI is downregulated and loses nuclear localization in colorectal cancer, reducing PABPN1 phase separation and thereby promoting alternative polyadenylation, cell proliferation, and migration. Identified via CRISPR/BiFC/FACS screen.\",\n      \"method\": \"CRISPR/Cas9-based screening with bimolecular fluorescence complementation (BiFC) and FACS, QKI knockdown/overexpression, APA analysis, cell proliferation and migration assays\",\n      \"journal\": \"Protein & cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR screen with BiFC readout plus functional validation, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"40052530\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PABPN1 is a nuclear poly(A)-binding protein that stimulates poly(A) polymerase and controls poly(A) tail length, regulates alternative polyadenylation site selection (suppressing proximal sites), promotes post-polyadenylation splicing of terminal introns via poly(A) tail-dependent recruitment of splicing factors (including RBM26/27), negatively autoregulates its own expression via intron retention coupled to nuclear exosome decay, undergoes mitotic kinase phosphorylation that remodels poly(A) tails to reset transcriptome dynamics across the cell cycle, forms liquid-liquid phase separation condensates (nuclear speckles/NPADs) driven by its N-terminal disordered domain and RNA-binding activity, has an unforeseen cytoplasmic function in recruiting DIS3L2 to uridylated maternal mRNAs for ZGA-dependent decay in embryos, interacts with MATR3, hnRNP A1/A/B, ZC3H11A, ARIH2, and mitochondrial TIM23 complex, and exerts anti-apoptotic activity through XIAP translation regulation; disease-causing polyalanine expansions promote aggregation from nuclear speckles in an RNA-dependent manner, sequestering CFIm25 and other factors while depleting functional soluble PABPN1, with soluble expanded protein (not aggregates) being the primary toxic species.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PABPN1 is a nuclear poly(A)-binding protein that governs the maturation, fate, and length control of polyadenylated transcripts through its RNA-binding and poly(A) polymerase-stimulatory functions [#17, #24]. It is recruited cotranscriptionally to nascent mRNPs and remains associated through nuclear export [#1, #11], and controls 3'-end processing by suppressing proximal polyadenylation sites and biasing toward distal site usage [#19, #29]. Beyond tail-length control, PABPN1 couples polyadenylation to splicing of terminal introns bearing weak 3' splice sites in a poly(A) tail-dependent manner, acting directly by recruiting the splicing factors RBM26/RBM27 [#26], and partners with MATR3 to coordinate alternative polyadenylation, intron retention, paraspeckle function, and A-to-I editing in muscle [#20]. PABPN1 negatively autoregulates its own expression by binding an adenosine-rich element in its 3' UTR, promoting terminal-intron retention and nuclear exosome-mediated clearance of its pre-mRNA [#16]. It forms liquid-liquid phase-separated nuclear poly(A) domains/speckles driven by its N-terminal disordered domain and RNA binding, a property essential for transcript stability and 3'UTR isoform formation in oocytes, with Pabpn1-null mice being sterile [#24]. Mitotic phosphorylation at four sites remodels poly(A) tails and tunes mRNA turnover to reset gene expression across the cell cycle [#30]. A cytoplasmic role has also been established whereby PABPN1 docks on 3'-uridylated maternal transcripts downstream of TUT4/7 and recruits the exoribonuclease DIS3L2 to drive zygotic genome activation-dependent maternal mRNA decay [#25]. PABPN1 additionally exerts an anti-apoptotic activity by regulating XIAP translation [#8]. Disease-causing N-terminal polyalanine expansions cause oculopharyngeal muscular dystrophy: expanded PABPN1 forms amyloid-like, RNA-dependent nuclear aggregates [#3, #29] that sequester partners including CFIm25 and hnRNP A1 [#2, #29], yet OPMD toxicity depends on the intrinsic RNA-binding function of PABPN1 rather than the polyalanine tract alone, and soluble expanded protein, not the insoluble aggregates, is the primary toxic species [#6, #7].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Established that PABPN1 oligomerization domains drive the nuclear aggregation seen with polyalanine expansion and that aggregation is mechanistically linked to cell death.\",\n      \"evidence\": \"Deletion mutagenesis with aggregation and cell-death readouts in COS-7 cells\",\n      \"pmids\": [\"11689481\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not resolve whether aggregates themselves or soluble species are toxic\", \"No structural basis for oligomerization\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Placed PABPN1 on the cotranscriptional mRNP, showing it loads near transcription start and accompanies mRNP to the nuclear pore, framing it as an early and persistent mRNP factor.\",\n      \"evidence\": \"Cryo-immunoelectron microscopy of Balbiani ring mRNP in Chironomus tentans\",\n      \"pmids\": [\"12749861\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single insect model system\", \"Does not define the molecular trigger for displacement at the pore\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identified hnRNP A1/A/B as PABPN1 partners and showed they are co-sequestered into mutant aggregates and patient inclusions, linking aggregation to partner depletion.\",\n      \"evidence\": \"Yeast two-hybrid, GST pull-down, Co-IP, and immunofluorescence in cells and OPMD muscle\",\n      \"pmids\": [\"12945950\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of hnRNP sequestration not quantified\", \"Direct interaction surface not mapped\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Demonstrated biophysically that expanded polyalanine drives amyloid-like fibril formation with seeding behavior, providing a structural model for OPMD aggregation.\",\n      \"evidence\": \"In vitro recombinant protein fibrillation and structural/seeding assays\",\n      \"pmids\": [\"14627730\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vitro only\", \"Relationship of fibrils to cellular toxicity unresolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Showed wild-type PABPN1 is intrinsically aggregation-prone and that inclusions are dynamic rather than irreversible, reframing aggregates as exchangeable reservoirs.\",\n      \"evidence\": \"FRAP and domain-deletion analysis in HeLa and C2 cells\",\n      \"pmids\": [\"15811916\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not establish whether dynamic exchange is protective or pathogenic\", \"PAP-stimulation domain requirement not mechanistically dissected\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Implicated HSP70/HSC70 chaperones in aggregate handling and showed pharmacological HSP70 induction reduces aggregate burden and cell death, identifying a tractable modifier.\",\n      \"evidence\": \"Pharmacological heat-shock induction with microscopy, solubility, and cell-death assays in HeLa\",\n      \"pmids\": [\"16239242\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cell-based only; no in vivo validation\", \"Off-target effects of inducers not excluded\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Established that OPMD muscle degeneration requires the RNA-binding function of PABPN1, not the polyalanine tract per se, redefining the disease as a property of PABPN1 function.\",\n      \"evidence\": \"Domain-specific mutants in a Drosophila OPMD model\",\n      \"pmids\": [\"16642034\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific RNA targets driving degeneration not identified\", \"Drosophila model may not capture all human muscle pathology\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Resolved the toxic-species question by showing soluble expanded PABPN1, not insoluble aggregates, is the primary toxic entity.\",\n      \"evidence\": \"Live microscopy and aggregate-disruption experiments with cell-death readout in a cellular OPMD model\",\n      \"pmids\": [\"17418585\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis of soluble-species toxicity not defined\", \"Single cellular model\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Defined an anti-apoptotic function for wild-type PABPN1 through regulation of XIAP translation, partially lost in the mutant, linking PABPN1 dosage to cell survival.\",\n      \"evidence\": \"Overexpression/knockdown in cell and mouse models with XIAP and apoptosis readouts\",\n      \"pmids\": [\"18178579\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of XIAP translational control not detailed\", \"Relevance to muscle pathology not established\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified the SIRT1/AMPK/FoxO axis as a genetic and pharmacological modifier of mutant PABPN1 muscle toxicity.\",\n      \"evidence\": \"C. elegans genetic epistasis plus sirtinol/resveratrol treatment of mammalian cells\",\n      \"pmids\": [\"18397876\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular link between SIRT1 and PABPN1 not established here\", \"Cross-species relevance uncertain\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Showed expanded PABPN1 preferentially recruits Hsp70 and type-I arginine methyltransferases (PRMT1/PRMT3), tying conformational change to altered partner binding.\",\n      \"evidence\": \"Pull-down, patient-muscle immunofluorescence, and molecular simulation\",\n      \"pmids\": [\"19641605\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of altered PRMT interaction untested\", \"Simulation-based conformational claim not experimentally confirmed\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Demonstrated via the fission yeast ortholog Pab2 that nuclear poly(A)-binding proteins are recruited cotranscriptionally ahead of canonical 3'-processing factors and persist on polysomes.\",\n      \"evidence\": \"RNase-sensitive ChIP, TAP-MS, and polysome fractionation in S. pombe\",\n      \"pmids\": [\"19336419\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ortholog-based; human conservation of polysome association not shown\", \"Recruitment mechanism not defined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Established a Pab2/exosome pathway for nuclear pre-mRNA decay opposed by Nab2, defining poly(A)-binding-protein competition as a decay-versus-stability switch.\",\n      \"evidence\": \"Genetic epistasis and RNA decay assays in S. pombe\",\n      \"pmids\": [\"24081329\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ortholog system\", \"Human equivalents of the competition not directly tested here\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Mapped a PY-NLS/Kap104 import route for Pab2 while showing human PABPN1 uses an alternative/redundant import pathway, distinguishing nuclear targeting mechanisms.\",\n      \"evidence\": \"NLS mutagenesis, receptor-binding, and nuclear localization assays across yeast and human\",\n      \"pmids\": [\"23279110\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Human import receptor not identified\", \"Redundancy not mapped\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defined PABPN1 negative autoregulation: it binds an A-rich element in its own 3' UTR to drive terminal-intron retention and exosome-mediated clearance, establishing dosage homeostasis.\",\n      \"evidence\": \"Dosage manipulation, spliced/unspliced ratio measurement, exosome knockdown, RNA-binding analysis\",\n      \"pmids\": [\"25963658\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative thresholds of the feedback loop not defined\", \"In vivo physiological role of autoregulation untested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Showed PABPN1 and PAP cooperate to promote excision of introns removed only after polyadenylation, requiring both RNA-binding and PAP-stimulatory functions and impaired by alanine expansion.\",\n      \"evidence\": \"RNAi depletion, splicing assays, domain mutants, and exosome assays\",\n      \"pmids\": [\"25896913\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Splicing factors recruited not yet identified at this stage\", \"Genome-wide scope not quantified\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstrated PABPN1 suppresses TDP-43 pathology by promoting its degradation and restoring solubility/localization, extending PABPN1 function to proteostasis of an aggregation-prone RBP.\",\n      \"evidence\": \"Overexpression/knockdown in cells and Drosophila with solubility, stress-granule, and localization readouts\",\n      \"pmids\": [\"26130692\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of TDP-43 clearance not defined\", \"Direct vs indirect effect unresolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Linked PABPN1 dosage to muscle physiology in vivo: reduced PABPN1 shifts toward proximal poly(A) sites, upregulating Atrogin-1 and causing myofiber atrophy.\",\n      \"evidence\": \"AAV-shRNA knockdown in mouse TA muscle with poly(A) site, expression, and histological analyses\",\n      \"pmids\": [\"27152426\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal chain from APA shift to atrophy not fully dissected\", \"Single muscle context\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Identified MATR3 as a PABPN1 partner in skeletal muscle and showed the pair jointly regulates APA, intron retention, paraspeckles, Neat1, and RNA editing.\",\n      \"evidence\": \"Co-IP/MS, RNAi, APA, paraspeckle, and RNA-editing assays in muscle cells\",\n      \"pmids\": [\"28977530\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Division of labor between PABPN1 and MATR3 on specific targets unresolved\", \"Interaction interface not mapped\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed PABPN1 controls SIRT1 mRNA via APA, connecting the earlier SIRT1 modifier genetics to a direct regulatory mechanism in muscle wasting.\",\n      \"evidence\": \"Multi-omics and sirtinol pharmacological rescue in shPAB mouse muscle\",\n      \"pmids\": [\"30739015\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Acetylome targets driving wasting not pinpointed\", \"Feedback between SIRT1 and PABPN1 not fully closed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Reported expanded PABPN1 accumulation in mitochondria and interaction with the TIM23 import complex, with OXPHOS deficits, extending pathology beyond the nucleus.\",\n      \"evidence\": \"Mitochondrial fractionation, TIM23 Co-IP, and patient/mouse tissue analysis\",\n      \"pmids\": [\"30894671\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of mitochondrial targeting unclear\", \"Causal contribution to OPMD pathology not established\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Extended PABPN1 translational control to p63α via eIF4E/eIF4G modulation and APA of p63γ, embedding it in a keratinocyte-differentiation feedback loop.\",\n      \"evidence\": \"siRNA knockdown, APA, eIF4E/eIF4G Co-IP, ΔNp63α rescue, differentiation assays\",\n      \"pmids\": [\"32243883\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect effect on initiation-factor binding unresolved\", \"Single tissue context\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established that PABPN1 drives liquid-liquid phase separation into nuclear poly(A) domains essential for oocyte transcript stability and 3'UTR isoform formation, with knockout causing sterility.\",\n      \"evidence\": \"Pabpn1 knockout mice, live phase-separation imaging, domain deletion, RNA-seq, and fertility assays\",\n      \"pmids\": [\"36306357\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Composition and regulation of NPADs incompletely defined\", \"Link between condensate formation and specific RNA fates partial\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Revealed an unforeseen cytoplasmic function: PABPN1 docks on 3'-uridylated maternal mRNAs downstream of TUT4/7 and recruits DIS3L2 for ZGA-dependent decay, with knockout embryos arresting at morula.\",\n      \"evidence\": \"Pabpn1 knockout mice, RIP, DIS3L2 Co-IP, and maternal-mRNA decay RNA-seq\",\n      \"pmids\": [\"34904664\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How nuclear vs cytoplasmic PABPN1 pools are partitioned unknown\", \"Structural basis of uridyl-transcript recognition not defined\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified the direct splicing mechanism: PABPN1 promotes excision of weak-3'SS last introns in a poly(A) tail-dependent manner by recruiting RBM26/RBM27, mapping the recruitment to RBM27 domains.\",\n      \"evidence\": \"Depletion, RNA tethering, TurboID-MS, and RBM27 Co-IP/domain mapping in HeLa and mouse cells\",\n      \"pmids\": [\"37661812\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How RBM26/27 execute splicing downstream not detailed\", \"Genome-wide intron selectivity rules incomplete\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed ZC3H11A requires PABPN1 for nuclear speckle localization and uses shared zinc fingers for PABPN1 and viral mRNA binding, linking PABPN1 to viral mRNA polyadenylation.\",\n      \"evidence\": \"Interactome MS, Co-IP, speckle localization, and viral mRNA polyadenylation analysis\",\n      \"pmids\": [\"37356722\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional role of ZC3H11A–PABPN1 complex in host mRNA processing unclear\", \"Competition between viral and host RNA not quantified\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Dissected PABPN1 aggregation as driven by both alanine expansion (controlling speckle mobility) and poly(A)-RNA (essential for condensation), with aggregates sequestering CFIm25 to impair APA.\",\n      \"evidence\": \"FRAP, poly(A) RNA binding, CFIm25 co-localization/function, and APA assays\",\n      \"pmids\": [\"37422193\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Quantitative relationship between sequestration and APA defects partial\", \"Reversibility of solid-like transition not tested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed SNRPD2 binds the EP domain of PABPN1 to disrupt its LLPS in colorectal cancer, de-repressing proximal poly(A) sites and shortening CTNNBIP1 3'UTR to promote tumor phenotypes.\",\n      \"evidence\": \"Phase-separation assays, domain-specific Co-IP, APA, and proliferation/migration assays\",\n      \"pmids\": [\"38811444\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Generality beyond CTNNBIP1 not established\", \"In vivo tumor relevance not tested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Established cell-cycle control of PABPN1: mitotic phosphorylation at four sites remodels poly(A) tails and tunes mRNA synthesis/decay to reset transcriptome dynamics.\",\n      \"evidence\": \"Phospho-site mutants with long-read poly(A) sequencing, TimeLapse-seq, and proliferation assays\",\n      \"pmids\": [\"38943343\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the responsible mitotic kinases not pinned down\", \"Specific affected mRNA cohorts incompletely characterized\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identified QKI as a positive regulator of PABPN1 LLPS, with its loss in colorectal cancer reducing phase separation and shifting APA toward pro-tumor isoforms.\",\n      \"evidence\": \"CRISPR/BiFC/FACS screen with QKI manipulation and APA/proliferation/migration assays\",\n      \"pmids\": [\"40052530\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which QKI promotes condensation unclear\", \"Therapeutic relevance untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How nuclear and cytoplasmic PABPN1 pools are spatially partitioned and switched between poly(A)-tail control, condensate formation, splicing, and DIS3L2-dependent decay remains undefined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model integrating RNA binding, LLPS, and partner recruitment\", \"Mitotic kinases and human nuclear import receptor unidentified\", \"Determinants of target selectivity across distinct functions unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [16, 17, 24, 26, 29]},\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [17, 26, 30]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [17, 25, 26]},\n      {\"term_id\": \"GO:0045182\", \"supporting_discovery_ids\": [8, 23]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [14, 16, 24]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [24, 27, 29]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [25]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [22]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [16, 17, 25, 26, 30]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [1, 11, 19]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 6, 7, 29]},\n      {\"term_id\": \"R-HSA-1474165\", \"supporting_discovery_ids\": [24, 25]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [30]}\n    ],\n    \"complexes\": [\"nuclear speckles / nuclear poly(A) domains (NPADs)\"],\n    \"partners\": [\"MATR3\", \"RBM27\", \"RBM26\", \"ZC3H11A\", \"DIS3L2\", \"HNRNPA1\", \"SNRPD2\", \"QKI\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":9,"faith_total":9,"faith_pct":100.0}}